Pretreatment oxygenation predicts radiation response a carcinoma of the head and neck

Radiotherapy and Oncology 41, 31-39 DOI: 10.1016/s0167-8140(96)01811-7

Citation Report

#	Article	IF	CITATIONS
1	A physical standard of the unit of electrical resistance based on the quantum Hall effect. Uspekhi Fizicheskikh Nauk, 1988, 31, 880-881.	0.3	8
2	The C1772T genetic polymorphism in human HIF-1α gene associates with expression of HIF-1α protein in breast cancer. Oncology Reports, 1994, 20, 1181.	1.2	1
3	Tumour Oxygenation Assessed by Polarographic Needle Electrodes and Bioenergetic Status Measured by ³¹ P Magnetic Resonance Spectroscopy in Human Soft Tissue Tumours. Acta Oncológica, 1997, 36, 565-571.	0.8	25
4	Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 8104-8109.	3.3	1,210
5	Measurement of Tumor Oxygenation: A Comparison between Polarographic Needle Electrodes and a Time-Resolved Luminescence-Based Optical Sensor. Radiation Research, 1997, 147, 329.	0.7	81
6	Longevity of Pimonidazole Adducts in Spontaneous Canine Tumors as an Estimate of Hypoxic Cell Lifetime. Radiation Research, 1997, 148, 35.	0.7	47
7	Cells at Intermediate Oxygen Levels Can Be More Important Than the "Hypoxic Fraction" in Determining Tumor Response to Fractionated Radiotherapy. Radiation Research, 1997, 147, 541.	0.7	288
8	Comments on Hyperbaric Oxygen and Carbogen/Nicotinamide with Fractionated Radiation. Radiation Research, 1997, 148, 526.	0.7	3
9	Oxygen tension in human tumours measured with polarographic needle electrodes and its relationship to vascular density, necrosis and hypoxia. Radiotherapy and Oncology, 1997, 44, 163-169.	0.3	73
10	Adaptation of human tumor cells to tirapazamine under aerobic conditions. Biochemical Pharmacology, 1997, 54, 249-257.	2.0	52
11	Detection of hypoxic cells in a C3H mouse mammary carcinoma using the comet assay. British Journal of Cancer, 1997, 76, 694-699.	2.9	28
12	Kinetics of mouse jejunum radiosensitization by 2',2'-difluorodeoxycytidine (gemcitabine) and its relationship with pharmacodynamics of DNA synthesis inhibition and cell cycle redistribution in crypt cells. British Journal of Cancer, 1997, 76, 1315-1321.	2.9	23
14	Role of oxygenation and vascularization in drug resistance. , 1998, 27, 249-256.		5
15	Colonisation ofClostridiumin the body is restricted to hypoxic and necrotic areas of tumours. Anaerobe, 1998, 4, 183-188.	1.0	85
16	Fraction of radiobiologically hypoxic cells in human melanoma xenografts measured by using single-cell survival, tumour growth delay and local tumour control as end points. British Journal of Cancer, 1998, 78, 893-898.	2.9	10
17	Radiotherapy and concurrent chemotherapy for the treatment of locally advanced head and neck squamous cell carcinoma. Seminars in Radiation Oncology, 1998, 8, 237-246.	1.0	49
18	Concepts of oxygen transport at the microcirculatory level. Seminars in Radiation Oncology, 1998, 8, 143-150.	1.0	145
19	A 2-week pretreatment with 13-cis-retinoic acid + interferon-α-2a prior to definitive radiation improves tumor tissue oxygenation in cervical cancers. Strahlentherapie Und Onkologie, 1998, 174, 571-574.	1.0	14

#	Article	IF	CITATIONS
20	Tumour Radiosensitization by High-Oxygen–Content Gases: Influence of the Carbon Dioxide Content of the Inspired Gas on pO2, Microcirculatory Function and Radiosensitivity. International Journal of Radiation Oncology Biology Physics, 1998, 40, 943-951.	0.4	56
21	Radiobiological Hypoxia in the KHT Sarcoma: Predictions Using the Eppendorf Histograph. International Journal of Radiation Oncology Biology Physics, 1998, 40, 1171-1176.	0.4	32
22	Oxygenation of squamous cell carcinoma of the head and neck: comparison of primary tumors, neck node metastases, and normal tissue. International Journal of Radiation Oncology Biology Physics, 1998, 42, 35-41.	0.4	121
23	Extravascular diffusion of tirapazamine: effect of metabolic consumption assessed using the multicellular layer model. International Journal of Radiation Oncology Biology Physics, 1998, 42, 641-649.	0.4	93
24	Preclinical evaluation of the novel hypoxic marker 99mTc-HL91 (prognox) in murine and xenograft systems in vivo. International Journal of Radiation Oncology Biology Physics, 1998, 42, 731-735.	0.4	31
25	Temporal changes in pO2 of R3230Ac tumors in fischer-344 rats. International Journal of Radiation Oncology Biology Physics, 1998, 42, 723-726.	0.4	70
26	Preclinical assessment of hypoxic marker specificity and sensitivity. International Journal of Radiation Oncology Biology Physics, 1998, 42, 741-745.	0.4	14
27	Heterogeneity of tumor oxygenation: relationship to tumor necrosis, tumor size, and metastasis. International Journal of Radiation Oncology Biology Physics, 1998, 42, 717-721.	0.4	54
28	Modulation of tumor oxygenation. International Journal of Radiation Oncology Biology Physics, 1998, 42, 843-848.	0.4	70
29	Measurement of tumor oxygenation. International Journal of Radiation Oncology Biology Physics, 1998, 42, 701-704.	0.4	80
30	Current Scientific Issues Related to Clinical Radiation Oncology. Radiation Research, 1998, 150, 125.	0.7	6
31	Molecular Biology to Radiation Oncology: A Model for Translational Research? Opportunities in Basic and Translational Research From a Workshop Sponsored by the National Cancer Institure, Radiation Research Program, January 26-28, 1997, Bethesda, Maryland. Radiation Research, 1998, 150, 134.	0.7	6
32	Reduction of Nitroarylmethyl Quaternary Ammonium Prodrugs of Mechlorethamine by Radiation. Radiation Research, 1998, 149, 237.	0.7	22
33	Lack of predictive value of potential doubling time and iododeoxyuridine labelling index in radiotherapy of squamous cell carcinoma of the head and neck. Radiotherapy and Oncology, 1998, 46, 147-155.	0.3	31
34	Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays. Radiotherapy and Oncology, 1998, 46, 229-237.	0.3	163
35	A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiotherapy and Oncology, 1998, 46, 135-146.	0.3	523
36	The effect of combined nicotinamide and carbogen treatments in human tumour xenografts: oxygenation and tumour control studies. Radiotherapy and Oncology, 1998, 48, 143-148.	0.3	22
37	Nodal CT density and total tumor volume as prognostic factors after radiation therapy of stage III/IV head and neck cancer. Radiotherapy and Oncology, 1998, 47, 175-183.	0.3	83

#	Article	IF	CITATIONS
38	Changes in tumor oxygenation during combined treatment with split-course radiotherapy and chemotherapy in patients with head and neck cancer. Radiotherapy and Oncology, 1998, 48, 157-164.	0.3	64
39	Accelerated radiotherapy with carbogen and nicotinamide (ARCON) for laryngeal cancer. Radiotherapy and Oncology, 1998, 48, 115-122.	0.3	103
40	Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiotherapy and Oncology, 1998, 48, 149-156.	0.3	568
41	Lack of perfusion enhancement after administration of nicotinamide and carbogen in patients with glioblastoma: a 99mTc-HMPAO SPECT study. Radiotherapy and Oncology, 1998, 48, 135-142.	0.3	21
42	Experimental Studies on the Possible Influence of Invasive Oxygen Measurements on Tumour Radiosensitivity. Acta Oncológica, 1998, 37, 369-373.	0.8	0
43	Tumor Hypoxia and Gene Expression: Implications for Malignant Progression and Therapy. Acta Oncológica, 1998, 37, 567-574.	0.8	108
44	Blood flow, oxygenation, metabolic and energetic status in different clonal subpopulations of a rat rhabdomyosarcoma International Journal of Oncology, 1998, 13, 205-11.	1.4	3
45	Exploiting tumour hypoxia and overcoming mutant p53 with tirapazamine. British Journal of Cancer, 1998, 77, 12-14.	2.9	25
46	Multiparameter analysis of vasculature, perfusion and proliferation in human tumour xenografts. British Journal of Cancer, 1998, 77, 57-64.	2.9	57
47	EPOETIN A ALFA IN RADIOTERAPIA. Tumori, 1998, 84, S15-S19.	0.6	1
48	Fourier analysis of fluctuations of oxygen tension and blood flow in R3230Ac tumors and muscle in rats. American Journal of Physiology - Heart and Circulatory Physiology, 1999, 277, H551-H568.	1.5	80
49	The OxyLite: a fibre-optic oxygen sensor British Journal of Radiology, 1999, 72, 627-630.	1.0	170
50	Changes in Oxygen Tension During Radiotherapy of Head and Neck Tumours. Acta Oncológica, 1999, 38, 1037-1042.	0.8	23
51	Clinical Outcome and Tumour Microenvironmental Effects of Accelerated Radiotherapy with Carbogen and Nicotinamide. Acta Oncológica, 1999, 38, 875-882.	0.8	27
52	Inducible Repair and the Two Forms of Tumour Hypoxia - Time for a Paradigm Shift. Acta Oncológica, 1999, 38, 903-918.	0.8	68
53	Dynamic contrast enhanced magnetic resonance scanning as a predictor of response to accelerated radiotherapy for advanced head and neck cancer British Journal of Radiology, 1999, 72, 1093-1098.	1.0	122
54	Synthesis of new hypoxia markers EF1 and [18F]-EF1. Applied Radiation and Isotopes, 1999, 51, 643-650.	0.7	33
55	Oxygenation of cervical cancers during radiotherapy and radiotherapy + cis-retinoic acid/interferon. International Journal of Radiation Oncology Biology Physics, 1999, 43, 367-373.	0.4	50

#	Article	IF	Citations
56	Phase I trial of the hypoxic cell cytotoxin tirapazamine with concurrent radiation therapy in the treatment of refractory solid tumors. International Journal of Radiation Oncology Biology Physics, 1999, 44, 349-353.	0.4	36
57	A comparison in individual murine tumors of techniques for measuring oxygen levels. International Journal of Radiation Oncology Biology Physics, 1999, 44, 1137-1146.	0.4	50
58	Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. International Journal of Radiation Oncology Biology Physics, 1999, 44, 749-754.	0.4	250
59	Oxygen tension measurements of tumors growing in mice. International Journal of Radiation Oncology Biology Physics, 1999, 45, 171-180.	0.4	44
60	RSR13, an allosteric effector of haemoglobin, and carbogen radiosensitize FSAII and SCCVII tumours in C3H mice. British Journal of Cancer, 1999, 79, 814-820.	2.9	21
61	In vitro radiosensitivity of tumour cells and fibroblasts derived from head and neck carcinomas: mutual relationship and correlation with clinical data. British Journal of Cancer, 1999, 79, 1074-1084.	2.9	16
62	The effects of hyperoxic and hypercarbic gases on tumour blood flow. British Journal of Cancer, 1999, 80, 117-126.	2.9	41
63	Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin. British Journal of Cancer, 1999, 80, 1245-1251.	2.9	65
64	A quantitative analysis of the reduction in oxygen levels required to induce up-regulation of vascular endothelial growth factor (VEGF) mRNA in cervical cancer cell lines. British Journal of Cancer, 1999, 80, 1518-1524.	2.9	46
65	Carbogen Inhalation in Cervical Cancer: Assessment of Oxygenation Change. Gynecologic Oncology, 1999, 74, 259-264.	0.6	20
67	Blood flow and oxygenation status of human tumors. Coloproctology, 1999, 21, 57-69.	0.3	3
68	Blood flow and oxygenation status of human tumors. Strahlentherapie Und Onkologie, 1999, 175, 1-9.	1.0	64
69	Tumoroxygenierung und Hypoxie. Onkologe, 1999, 5, 1000-1007.	0.7	5
70	Tissue oxygen distribution in head and neck cancer patients. , 1999, 21, 146-153.		77
71	Comparison of the effectiveness of tirapazamine and carbogen with nicotinamide in enhancing the response of a human tumor xenograft to fractionated irradiation. Radiation Oncology Investigations, 1999, 7, 163-169.	1.3	7
72	Radiotherapy: the last 25 years. Cancer Treatment Reviews, 1999, 25, 365-376.	3.4	23
73	Rise of oxygenation in cervical lymph node metastasis during the initial course of radiochemotherapy. Otolaryngology - Head and Neck Surgery, 1999, 121, 789-796.	1.1	8
74	DNA Damage Measured by the Comet Assay in Head and Neck Cancer Patients Treated with Tirapazamine. Neoplasia, 1999, 1, 461-467.	2.3	34

#	Article	IF	CITATIONS
75	Hypoxic regions exist in human prostate carcinoma. Urology, 1999, 53, 11-18.	0.5	160
76	Relationship between tumour cell in vitro radiosensitivity and clinical outcome after curative radiotherapy for squamous cell carcinoma of the head and neck. Radiotherapy and Oncology, 1999, 50, 47-55.	0.3	36
77	Normobaric oxygen treatment during radiotherapy for carcinoma of the uterine cervix. Results from a prospective controlled randomized trial. Radiotherapy and Oncology, 1999, 50, 157-165.	0.3	6
78	Vascular architecture and microenvironmental parameters in human squamous cell carcinoma xenografts: effects of carbogen and nicotinamide. Radiotherapy and Oncology, 1999, 50, 173-184.	0.3	62
79	Comparison between the comet assay and the oxygen microelectrode for measurement of tumor hypoxia. Radiotherapy and Oncology, 1999, 51, 179-185.	0.3	34
80	Monitoring of tumor reoxygenation following irradiation by 31P magnetic resonance spectroscopy: an experimental study of human melanoma xenografts. Radiotherapy and Oncology, 1999, 52, 261-267.	0.3	8
81	Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiotherapy and Oncology, 1999, 53, 113-117.	0.3	518
82	Polarographic measurements of oxygen tension in human glioma and surrounding peritumoural brain tissue. Radiotherapy and Oncology, 1999, 53, 127-131.	0.3	165
83	Tumoural perfusion as measured by dynamic computed tomography in head and neck carcinoma. Radiotherapy and Oncology, 1999, 53, 105-111.	0.3	75
84	Intratumoral pO2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix. Radiotherapy and Oncology, 1999, 53, 99-104.	0.3	213
85	The Use of Needle Biopsies for Radiobiological Assessment of Oxygen Levels in KHT-C Tumors. Radiation Research, 1999, 152, 107.	0.7	3
86	Recombinant Human Erythropoietin in the Treatment of Cancer. , 1999, 50, 106-114.		0
87	Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age. Cancer, 2000, 89, 2018-2024.	2.0	36
88	Review of methods used to study oxygen transport at the microcirculatory level. International Journal of Cancer, 2000, 90, 237-255.	2.3	82
89	Evidence of cell kinetics as predictive factor of response to radiotherapy alone or chemoradiotherapy in patients with advanced head and neck cancer. International Journal of Radiation Oncology Biology Physics, 2000, 47, 57-63.	0.4	16
90	Tumor radiosensitivity: it's the subpopulations that count. International Journal of Radiation Oncology Biology Physics, 2000, 47, 549-550.	0.4	4
91	Changes in tumor hypoxia measured with a double hypoxic marker technique. International Journal of Radiation Oncology Biology Physics, 2000, 48, 1529-1538.	0.4	89
92	Anemia is associated with decreased local control of surgically treated squamous cell carcinomas of the glottic larynx. International Journal of Radiation Oncology Biology Physics, 2000, 48, 1345-1350.	0.4	52

#	Article	IF	CITATIONS
93	Hypoxia and necrosis in rat 9L glioma and Morris 7777 hepatoma tumors: comparative measurements using EF5 binding and the Eppendorf needle electrode. International Journal of Radiation Oncology Biology Physics, 2000, 46, 1005-1017.	0.4	53
94	Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas. International Journal of Radiation Oncology Biology Physics, 2000, 46, 459-466.	0.4	211
95	Changes in tumor oxygen tension during radiotherapy of uterine cervical cancer: relationships to changes in vascular density, cell density, and frequency of mitosis and apoptosis. International Journal of Radiation Oncology Biology Physics, 2000, 46, 935-946.	0.4	45
96	Development of a hypoxia-responsive vector for tumor-specific gene therapy. Gene Therapy, 2000, 7, 493-498.	2.3	256
97	Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Trends in Molecular Medicine, 2000, 6, 157-162.	2.6	323
98	Influence of p53 and bcl-2 on proliferative activity and treatment outcome in head and neck cancer patients. Oral Oncology, 2000, 36, 54-60.	0.8	14
99	Comparison of aromatic and tertiary amine N-oxides of acridine DNA intercalators as bioreductive drugs. Biochemical Pharmacology, 2000, 60, 969-978.	2.0	30
100	Hypoxia-Dependent Retinal Toxicity of Bioreductive Anticancer Prodrugs in Mice. Toxicology and Applied Pharmacology, 2000, 163, 50-59.	1.3	64
101	Disparate responses of tumour vessels to angiotensin II: tumour volume-dependent effects on perfusion and oxygenation. British Journal of Cancer, 2000, 83, 225-231.	2.9	24
102	Vascular architecture and hypoxic profiles in human head and neck squamous cell carcinomas. British Journal of Cancer, 2000, 83, 674-683.	2.9	84
104	Prognostic Value of Hemoglobin Concentrations in Patients with Advanced Head and Neck Cancer Treated with Combined Radio-Chemotherapy and Surgery. Strahlentherapie Und Onkologie, 2000, 176, 73-80.	1.0	34
105	Prognostic Significance of Anemia and Role of Erythropoietin in Radiation Therapy. Tumori, 2000, 86, 17-23.	0.6	11
107	Radiation-Induced DNA Damage in Tumors and Normal Tissues. VI. Estimation of the HypoxicFraction of Experimental Tumors1. Radiation Research, 2000, 153, 548-556.	0.7	1
108	Feasibility of Detecting Hypoxia in Experimental Mouse Tumours with18F-fluorinated Tracers and Positron Emission Tomography: A Study Evaluating [18F]Fluoromisonidazole and [18F]Fluoro-2-deoxy-D-glucose. Acta Oncológica, 2000, 39, 629-637.	0.8	70
109	Measurement of Hypoxia Using the Comet Assay Correlates with Preirradiation MicroelectrodepO2Histography in R3327-AT Rodent Tumors. Radiation Research, 2000, 154, 439-446.	0.7	10
110	Determining Hypoxic Fraction in a Rat Glioma by Uptake of Radiolabeled Fluoromisonidazole. Radiation Research, 2000, 153, 84-92.	0.7	54
111	Changes in Blood Perfusion and Hypoxia after Irradiation of a Human Squamous Cell Carcinoma Xenograft Tumor Line. Radiation Research, 2000, 153, 398-404.	0.7	86
112	Prognostic assessment of sonography and tumor volumetry in advanced cancer of the head and neck by use of Doppler ultrasonography. Otolaryngology - Head and Neck Surgery, 2000, 122, 596-601.	1.1	17

#	Article	IF	CITATIONS
113	Oxygenation of advanced head and neck cancerâ~†Prognostic marker for the response to primary radiochemotherapy. Otolaryngology - Head and Neck Surgery, 2000, 122, 856-862.	1.1	24
114	Prognostic assessment of sonography and tumor volumetry in advanced cancer of the head and neck by use of Doppler ultrasonographyâ~†. Otolaryngology - Head and Neck Surgery, 2000, 122, 596-601.	1.1	8
115	Hypoxic cytotoxic agents: a new approach to cancer chemotherapy. Drug Resistance Updates, 2000, 3, 7-13.	6.5	20
117	Prognostic significance of cervical lymph nodes density evaluated by contrasted computer tomography in head and neck squamous cell carcinoma treated with hyperthermia and radiotherapy. International Journal of Hyperthermia, 2000, 16, 539-547.	1.1	3
118	Optical Sensor-Based Oxygen Tension Measurements Correspond with Hypoxia Marker Binding in Three Human Tumor Xenograft Lines. Radiation Research, 2000, 154, 547-555.	0.7	37
119	ARCON: accelerated radiotherapy with carbogen and nicotinamide in head and neck squamous cell carcinomas. The experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer (EORTC). Radiotherapy and Oncology, 2000, 55, 111-119.	0.3	53
120	Repeatability and prognostic impact of the pretreatment pO2 histography in patients with advanced head and neck cancer. Radiotherapy and Oncology, 2000, 57, 31-37.	0.3	85
121	Diffusion limited hypoxia estimated by vascular image analysis: comparison with pimonidazole staining in human tumors. Radiotherapy and Oncology, 2000, 55, 325-333.	0.3	25
122	A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiotherapy and Oncology, 2000, 57, 39-43.	0.3	274
123	Targeting tumor blood vessels: an adjuvant strategy for radiation therapy. Radiotherapy and Oncology, 2000, 57, 5-12.	0.3	60
124	Anemia, hypoxia and transfusion in patients with cervix cancer: a review. Radiotherapy and Oncology, 2000, 57, 13-19.	0.3	125
125	Tumour oxygenation levels correlate with dynamic contrast-enhanced magnetic resonance imaging parameters in carcinoma of the cervix. Radiotherapy and Oncology, 2000, 57, 53-59.	0.3	197
126	Estimation of tumour oxygenation levels with dynamic contrast-enhanced magnetic resonance imaging. Radiotherapy and Oncology, 2000, 57, 1-3.	0.3	8
127	Effects of nicotinamide and carbogen on oxygenation in human tumor xenografts measured with luminescense based fiber-optic probes. Radiotherapy and Oncology, 2000, 57, 21-30.	0.3	56
128	Mathematical modeling of chronical hypoxia in tumors considering potential doubling time and hypoxic cell lifetime. Radiotherapy and Oncology, 2000, 54, 171-177.	0.3	17
129	Hypoxia and VEGF mRNA Expression in Human Tumors. Neoplasia, 2001, 3, 500-508.	2.3	50
130	Green Fluorescent Protein is a Suitable Reporter of Tumor Hypoxia Despite an Oxygen Requirement for Chromophore Formation. Neoplasia, 2001, 3, 527-534.	2.3	96
131	Oxygenation of human tumors—implications for combined therapy. Lung Cancer, 2001, 33, S77-S83.	0.9	17

		CITATION REF	PORT	
#	Article		IF	CITATIONS
132	Imaging hypoxia in tumors. Seminars in Nuclear Medicine, 2001, 31, 321-329.		2.5	117
133	Increased hypoxia correlates with increased expression of the angiogenesis marker vasce endothelial growth factor in human prostate cancer. Urology, 2001, 57, 821-825.	ılar	0.5	74
134	Tumor Hypoxia: Definitions and Current Clinical, Biologic, and Molecular Aspects. Journa National Cancer Institute, 2001, 93, 266-276.	l of the	3.0	2,581
135	Biological Predictors of Response to Radiotherapy in Head and Neck Cancer: Recent Adv Emerging Perspectives. Tumori, 2001, 87, 355-363.	ances and	0.6	18
136	Comparison of tumor and normal tissue oxygen tension measurements using OxyLite or microelectrodes in rodents. American Journal of Physiology - Heart and Circulatory Physic 280, H2533-H2544.	ology, 2001,	1.5	242
137	Prognostic Radiology: Quantitative Assessment of Tumor Oxygen Dynamics by MRI. Amo of Clinical Oncology: Cancer Clinical Trials, 2001, 24, 462-466.	erican Journal	0.6	40
138	Functional CT Imaging of the Acute Hyperemic Response to Radiation Therapy of the Pro Early Experience. Journal of Computer Assisted Tomography, 2001, 25, 43-49.	state Gland:	0.5	51
139	Editorial. Nuclear Medicine Communications, 2001, 22, 945-947.		0.5	3
140	Phase Ia study of a hypoxic cell sensitizer doranidazole (PR-350) in combination with cor radiotherapy. Anti-Cancer Drugs, 2001, 12, 1-6.	iventional	0.7	28
141	Hypoxia in Human Prostate Carcinoma. American Journal of Clinical Oncology: Cancer Cl 2001, 24, 458-461.	inical Trials,	0.6	100
142	Chromatin Compaction and Tumor Cell Radiosensitivity at 2 Gray. American Journal of C Oncology: Cancer Clinical Trials, 2001, 24, 509-515.	inical	0.6	15
143	99Tcm labelled HL91 versus computed tomography and biopsy for the visualization of the recurrence of squamous head and neck carcinoma. Nuclear Medicine Communications, 2269-275.	ımour 2001, 22,	0.5	23
144	Predictive Value of the Tumor Oxygenation by Means of pO2 Histography in Patients wit Head and Neck Cancer. Strahlentherapie Und Onkologie, 2001, 177, 462-468.	h Advanced	1.0	90
145	Prognostic Impact of Tumor Perfusion in MR-Imaging Studies in Ewing Tumors. Strahlent Onkologie, 2001, 177, 153-159.	herapie Und	1.0	28
146	Recombinant human erythropoietin increases the radiosensitivity of xenografted human anaemic nude mice. Journal of Cancer Research and Clinical Oncology, 2001, 127, 346-3	tumours in 50.	1.2	73
147	Tumor oximetry: demonstration of an enhanced dynamic mapping procedure using fluor planar magnetic resonance imaging in the Dunning prostate R3327-AT1 rat tumor. Inter of Radiation Oncology Biology Physics, 2001, 49, 1097-1108.	ine-19 echo hational Journal	0.4	111
148	In vivo evaluation of a novel antitumor prodrug, 1-(2′-oxopropyl)-5-fluorouracil (OFUC releases 5-fluorouracil upon hypoxic irradiation. International Journal of Radiation Oncold Biology Physics, 2001, 49, 407-413.	i01), which ogy	0.4	36
149	Invasive oxygen measurements and pimonidazole labeling in human cervix carcinoma. In Journal of Radiation Oncology Biology Physics, 2001, 49, 581-586.	ternational	0.4	79

ARTICLE IF CITATIONS Hypoxia in human intraperitoneal and extremity sarcomas. International Journal of Radiation 150 0.4 40 Oncology Biology Physics, 2001, 49, 587-596. Tumor oxygenation after radiotherapy, chemotherapy, and/or hyperthermia predicts tumor free survival. International Journal of Radiation Oncology Biology Physics, 2001, 49, 1119-1125. 0.4 A Phase I study of RSR13, a radiation-enhancing hemoglobin modifier: tolerance of repeated intravenous doses and correlation of pharmacokinetics with pharmacodynamics. International 152 0.4 36 Journal of Radiation Oncology Biology Physics, 2001, 49, 1133-1139. The relation of CT-determined tumor parameters and local and regional outcome of tonsillar cancer after definitive radiation treatment. International Journal of Radiation Oncology Biology Physics, 2001, 50, 37-45. Nuclear expression of human apurinic/apyrimidinic endonuclease (HAP1/Ref-1) in head-and-neck cancer is associated with resistance to chemoradiotherapy and poor outcome. International Journal of Radiation Oncology Biology Physics, 2001, 50, 27-36. 154 0.4 104 Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. International Journal of Radiation Oncology Biology Physics, 2001, 50, 705-715. 0.4 250 Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck 156 0.4 469 cancer. International Journal of Radiation Oncology Biology Physics, 2001, 51, 349-353. Tumor size and oxygenation are independent predictors of nodal diseases in patients with cervix 0.4 74 cancer. International Journal of Radiation Oncology Biology Physics, 2001, 51, 699-703. MIB-1 and p53 expression in radiotherapy-resistant T1aNOMO glottic squamous cell carcinoma. Clinical 158 0.0 9 Otolaryngology, 2001, 26, 227-230. Role of multimodal treatment in oropharynx, larynx, and hypopharynx cancer. Journal of Surgical 159 1.4 14 Oncology, 2001, 20, 66-74. Impact of hemoglobin levels before and during concurrent chemoradiotherapy on the response of 160 72 2.0 treatment in patients with cervical carcinoma. Cancer, 2001, 92, 903-908. Role of protein kinase C? in transmitting hypoxia signal to HSF and HIF-1. Journal of Cellular 50 Physiology, 2001, 188, 223-235. Intermittent blood flow in solid tumours--an under-appreciated source of 'drug resistance'. Cancer 162 2.7 60 and Metastasis Reviews, 2001, 20, 57-61. Treatment Resistance of Solid Tumors. Medical Oncology, 2001, 18, 243-260. 1.2 471 Relationship of hypoxia to metastatic ability in rodent tumours. British Journal of Cancer, 2001, 84, 164 2.9 82 1280-1285. Effects of hyperbaric oxygen and normobaric carbogen on the radiation response of the rat rhabdomyosarcoma R1H 1 1This work was partially financed by the German Cancer Aid and the Fonds 23 Ophthalmopathy, AMC Amsterdam, The Netherlands.. International Journal of Radiation Oncology Biology Physics. 2001. 51. 1037-1044. Gene transfer of antisense hypoxia inducible factor-1 α enhances the therapeutic efficacy of cancer 166 2.3148 immunotherapy. Gene Therapy, 2001, 8, 638-645. Metabolism of tirapazamine by multiple reductases in the nucleus11Abbreviations: IPZ, tirapazamine; P450 reductase, NADPH:cytochrome P450 reductase; PMSF, phenylmethylsulfonyl fluoride; DTT dithiothreitol; DHR123, dihydrorhodamine 123; DAPI, 4′,6-diamidino-2-phenylindole, dihydrochloride; SN, 54 supernatant from nuclei; LŚ, low salt; HS, high salt; and NM, nuclear matrix.. Biochemical

#	Article	IF	CITATIONS
168	Single-photon emission computed tomography and positron-emission tomography assays for tissue oxygenation. Seminars in Radiation Oncology, 2001, 11, 47-57.	1.0	58
169	Magnetic resonance imaging applications in the evaluation of tumor angiogenesis*. Seminars in Radiation Oncology, 2001, 11, 70-82.	1.0	55
170	Hypoxia activates Akt and induces phosphorylation of GSK-3 in PC12 cells. Cellular Signalling, 2001, 13, 23-27.	1.7	110
171	Prognostic Value of Histopathological Response to Radiotherapy and Microvessel Density in Oral Squamous Cell Carcinomas. Acta Oncológica, 2001, 40, 491-496.	0.8	11
172	Radiobiological Hypoxia, Oxygen Tension, Interstitial Fluid Pressure and Relative Viable Tumour Area in Two Human Squamous Cell Carcinomas in Nude Mice During Fractionated Radiotherapy. Acta Oncológica, 2001, 40, 519-528.	0.8	22
173	Microvessel density predicts the radiosensitivity of metastatic head and neck squamous cell carcinoma in cervical lymph nodes. International Journal of Oncology, 2001, 19, 1127-32.	1.4	7
174	Hypoxia in human soft tissue sarcomas: Adverse impact on survival and no association with p53 mutations. British Journal of Cancer, 2001, 84, 1070-1075.	2.9	204
175	Measuring Hypoxia in Solid Tumours&Is There a Gold Standard?. Acta Oncológica, 2001, 40, 917-923.	0.8	62
176	Effects of the Interaction between Carbogen and Nicotinamide on R3230 Ac Tumor Blood Flow in Fischer 344 Rats. Radiation Research, 2001, 155, 724-733.	0.7	7
177	Radiobiological Hypoxia, Oxygen Tension, Interstitial Fluid Pressure and Relative Viable Tumour Area in Two Human Squamous Cell Carcinomas in Nude Mice During Fractionated Radiotherapy. Acta Oncológica, 2001, 40, 519-528.	0.8	25
178	Radiosensitizing Effect of Carbogen Breathing during Pulsed Irradiation of the Rat R1H Tumor. Acta Oncológica, 2001, 40, 870-874.	0.8	2
179	Targeting Hypoxia in Head and Neck Cancer. Acta OncolÃ ³ gica, 2001, 40, 937-940.	0.8	20
180	TheKmfor Radiosensitization of Human Tumor Cells by Oxygen is Much Greater than 3 mmHg and is Further Increased by Elevated Levels of Cysteine. Radiation Research, 2001, 156, 388-398.	0.7	36
181	Levels of Hypoxia-Inducible Factor-1Â During Breast Carcinogenesis. Journal of the National Cancer Institute, 2001, 93, 309-314.	3.0	554
182	Impact of Tumor Hypoxia and Anemia on Radiation Therapy Outcomes. Oncologist, 2002, 7, 492-508.	1.9	320
183	Tumor Hypoxia Has Independent Predictor Impact Only in Patients With Node-Negative Cervix Cancer. Journal of Clinical Oncology, 2002, 20, 680-687.	0.8	255
184	Tumor Microenvironment and the Response to Anticancer Therapy. Cancer Biology and Therapy, 2002, 1, 453-458.	1.5	215
185	Estimating DNA Repair by Sequential Evaluation of Head and Neck Tumor Radiation Sensitivity Using the Comet Assay. JAMA Otolaryngology, 2002, 128, 698.	1.5	19

#	Article	IF	CITATIONS
186	Oxygen measurement in living cells: comparison between a new vital fluorescent pyrene probe labeling mitochondria and pyrene butyric acid. , 2002, 4622, 1.		4
187	Pathways of Reductive Fragmentation of Heterocyclic Nitroarylmethyl Quaternary Ammonium Prodrugs of Mechlorethamine. Radiation Research, 2002, 158, 753-762.	0.7	15
188	Sensitizing and Protective Substances in Radiation Therapy and Predictive Assays. Acta Oncológica, 2002, 41, 615-622.	0.8	7
189	Carbogen Breathing after Irradiation Enhances the Effectiveness of Tirapazamine in SiHa Tumors but not SCCVII Tumors in Mice. Radiation Research, 2002, 158, 94-100.	0.7	2
190	The Range of Oxygenation in SiHa Tumor Xenografts. Radiation Research, 2002, 158, 159-166.	0.7	18
191	Raising Hemoglobin: An Opportunity for Increasing Survival?. Oncology, 2002, 63, 19-28.	0.9	31
192	<title>Optical properties of blood at various levels of oxygenation studied by time-resolved detection of laser-induced pressure profiles</title> ., 2002, 4618, 63.		17
193	Hypoxia Stimulates p16 Expression and Association with cdk4. Experimental Cell Research, 2002, 278, 53-60.	1.2	22
194	Pharmacology and toxicity of nicotinamide combined with domperidone during fractionated radiotherapy. Radiotherapy and Oncology, 2002, 63, 285-291.	0.3	19
195	Hypoxic prostate/muscle po2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findings. Urology, 2002, 60, 634-639.	0.5	178
196	Hypoxia as a target for combined modality treatments. European Journal of Cancer, 2002, 38, 240-257.	1.3	167
197	Molecular approaches to chemo-radiotherapy. European Journal of Cancer, 2002, 38, 231-239.	1.3	38
198	Hypoxia-Inducible Regulation of a Prodrug-Activating Enzyme for Tumor-Specific Gene Therapy. Neoplasia, 2002, 4, 40-48.	2.3	67
199	Hypoxia imaging in brain tumors. Neuroimaging Clinics of North America, 2002, 12, 537-552.	0.5	46
200	Tumor Responses to Radiation Therapy. Academic Radiology, 2002, 9, S215-S219.	1.3	4
201	Tumor Hypoxia Has Independent Predictor Impact Only in Patients With Node-Negative Cervix Cancer. Journal of Clinical Oncology, 2002, 20, 680-687.	0.8	348
202	Assessment of Cancer-Associated Biomarkers by Positron Emission Tomography: Advances and Challenges. Disease Markers, 2002, 18, 211-247.	0.6	23
203	Tirapazamine: Prototype for a novel class of therapeutic agents targeting tumor hypoxia. Seminars in Oncology, 2002, 29, 102-109.	0.8	56

CITAT	LON	DEDODT	
U.I.I.A	HON.	KEPORI	

#	Article	IF	CITATIONS
204	The importance of tumor metabolism in cancer prognosis and therapy; pre-clinical studies on rodent tumors with agents that improve tumor oxygenation. Advances in Enzyme Regulation, 2002, 42, 131-141.	2.9	5
205	Expression of hypoxia-inducible factor-1? in oligodendrogliomas. Cancer, 2002, 94, 2317-2318.	2.0	5
207	De novo establishment and cost-effectiveness of Papanicolaou Cytology Screening Services in the Socialist Republic of Vietnam. Cancer, 2002, 94, 2312-2314.	2.0	6
209	Visual estimate of the percentage of carcinoma is an independent predictor of prostate carcinoma recurrence after radical prostatectomy. Cancer, 2002, 94, 2310-2311.	2.0	1
211	The New American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer, 2002, 94, 2305-2307.	2.0	15
212	A high number of tumor free axillary lymph nodes from patients with lymph node negative breast carcinoma is associated with poor outcome. Cancer, 2002, 94, 2307-2309.	2.0	8
213	Author reply to previously published correspondence. Cancer, 2002, 94, 2316-2317.	2.0	0
214	Assessment of morphometric measurements of prostate carcinoma volume. Cancer, 2002, 94, 2309-2310.	2.0	0
215	Quantitative assessment of tumor oxygen dynamics: Molecular imaging for prognostic radiology. Journal of Cellular Biochemistry, 2002, 87, 45-53.	1.2	26
216	Tumor hypoxia and the progression of prostate cancer. Current Urology Reports, 2002, 3, 222-228.	1.0	33
217	Oxygenation Measurements in Head and Neck Cancers during Hyperbaric Oxygenation. Strahlentherapie Und Onkologie, 2002, 178, 105-108.	1.0	34
218	Tumor oxygenation under combined whole-body-hyperthermia and polychemotherapy in a case of recurrent carcinoma of the oral cavity. European Archives of Oto-Rhino-Laryngology, 2002, 259, 27-31.	0.8	6
219	Phase 1 study to identify tumour hypoxia in patients with head and neck cancer using technetium-99m BRU 59-21. European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29, 1206-1211.	3.3	29
220	Accelerated superfractionated radiotherapy with concomitant boost for locally advanced head-and-neck squamous cell carcinomas. International Journal of Radiation Oncology Biology Physics, 2002, 52, 918-928.	0.4	9
221	Differential oxygen dynamics in two diverse Dunning prostate R3327 rat tumor sublines (MAT-Lu and) Tj ETQqO Biology Physics, 2002, 53, 744-756.	0 0 rgBT /(0.4	Overlock 10 T 48
222	Effects of breathing a hyperoxic hypercapnic gas mixture on blood oxygenation and vascularity of head-and-neck tumors as measured by magnetic resonance imaging. International Journal of Radiation Oncology Biology Physics, 2002, 53, 1185-1191.	0.4	111
223	Increased radiosensitivity with chronic hypoxia in four human tumor cell lines. International Journal of Radiation Oncology Biology Physics, 2002, 54, 910-920.	0.4	77
224	HIF-1α, pimonidazole, and iododeoxyuridine to estimate hypoxia and perfusion in human head-and-neck tumors. International Journal of Radiation Oncology Biology Physics, 2002, 54, 1537-1549.	0.4	364

#	Article	IF	CITATIONS
225	Expression of hypoxia-inducible factor-1α in cervical carcinomas: correlation with tumor oxygenation. International Journal of Radiation Oncology Biology Physics, 2002, 53, 854-861.	0.4	348
226	Vascular architecture, hypoxia, and proliferation in first-generation xenografts of human head-and-neck squamous cell carcinomas. International Journal of Radiation Oncology Biology Physics, 2002, 54, 215-228.	0.4	120
227	Prediction of radiotherapy outcome using dynamic contrast enhanced MRI of carcinoma of the cervix. International Journal of Radiation Oncology Biology Physics, 2002, 54, 759-767.	0.4	165
228	The Effect of Smoking on Tumour Oxygenation and Treatment Outcome in Cervical Cancer. Clinical Oncology, 2002, 14, 442-446.	0.6	12
229	Inhibitory effect of a naphthazarin derivative, S64, on heat shock factor (Hsf) activation and glutathione status following hypoxia. Cell Biology and Toxicology, 2003, 19, 273-284.	2.4	7
230	Preferential elevation of Prx I and Trx expression in lung cancer cells following hypoxia and in human lung cancer tissues. Cell Biology and Toxicology, 2003, 19, 285-298.	2.4	94
231	The hypoxic tumour microenvironment and metastatic progression. Clinical and Experimental Metastasis, 2003, 20, 237-250.	1.7	310
232	Antioxidants in cancer therapy: Is there a rationale to recommend antioxidants during cancer therapy?. BioFactors, 2003, 17, 229-240.	2.6	11
233	Quantifying tumour hypoxia with fluorine-18 fluoroerythronitroimidazole ([18 F]FETNIM) and PET using the tumour to plasma ratio. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 101-108.	3.3	76
234	Oxygenation Status of Cervical Carcinomas Before and During Spinal Anesthesia for Application of Brachytherapy. Strahlentherapie Und Onkologie, 2003, 179, 633-640.	1.0	16
235	Clinical markers of hypoxia and other predictive factors of survival in conservative therapy of squamous-cell carcinoma of the esophagus. International Journal of Colorectal Disease, 2003, 18, 167-171.	1.0	4
236	Modulation of cell death in the tumor microenvironment. Seminars in Radiation Oncology, 2003, 13, 31-41.	1.0	91
237	Improved potency of the hypoxic cytotoxin tirapazamine by DNA-targeting. Biochemical Pharmacology, 2003, 65, 1807-1815.	2.0	31
238	Prognostic impact of reoxygenation in advanced cancer of the head and neck during the initial course of chemoradiation or radiotherapy alone. Head and Neck, 2003, 25, 50-58.	0.9	28
239	GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: Relationship to pimonidazole binding. International Journal of Cancer, 2003, 104, 85-91.	2.3	205
240	How to overcome (and exploit) tumor hypoxia for targeted gene therapy. Journal of Cellular Physiology, 2003, 197, 312-325.	2.0	64
241	Nuclear medicine imaging to predict response to radiotherapy: a review. International Journal of Radiation Oncology Biology Physics, 2003, 55, 5-15.	0.4	82
242	Comparison of the comet assay and the oxygen microelectrode for measuring tumor oxygenation in head-and-neck cancer patients. International Journal of Radiation Oncology Biology Physics, 2003, 56, 375-383.	0.4	40

#	Article	IF	CITATIONS
243	Significant correlation of hypoxia-inducible factor-1α with treatment outcome in cervical cancer treated with radical radiotherapy. International Journal of Radiation Oncology Biology Physics, 2003, 56, 494-501.	0.4	117
244	Erythropoietin restores the anemia-induced reduction in radiosensitivity of experimental human tumors in nude mice. International Journal of Radiation Oncology Biology Physics, 2003, 55, 1358-1362.	0.4	77
245	Evaluation of hypoxia-inducible factor-1α (HIF-1α) as an intrinsic marker of tumor hypoxia in U87 MG human glioblastoma: In vitro and xenograft studies. International Journal of Radiation Oncology Biology Physics, 2003, 56, 1184-1193.	0.4	59
246	Microfluorometric study of oxygen dependence of (1″-pyrene butyl)-2-rhodamine ester probe in mitochondria of living cells. Journal of Photochemistry and Photobiology B: Biology, 2003, 70, 107-115.	1.7	15
247	The Effect of Deep Inspiration Breath-hold on Tumour Oxygenation. Clinical Oncology, 2003, 15, 386-393.	0.6	0
248	Differential, stage-dependent expression of Hsp70, Hsp110 and Bcl-2 in colorectal cancer. Journal of Gastroenterology and Hepatology (Australia), 2003, 18, 690-700.	1.4	105
249	Chemoradiation: A new approach for the treatment of cervical cancer. International Journal of Gynecological Cancer, 2003, 13, 580-586.	1.2	23
250	Anemia before and during concurrent chemoradiotherapy in patients with cervical carcinoma: Effect on progression-free survival. International Journal of Gynecological Cancer, 2003, 13, 633-639.	1.2	30
251	Glucose transporter-1 (GLUT-1): a potential marker of prognosis in rectal carcinoma?. British Journal of Cancer, 2003, 89, 870-876.	2.9	100
252	GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON. British Journal of Cancer, 2003, 89, 1290-1297.	2.9	194
253	Investigating hypoxic tumor physiology through gene expression patterns. Oncogene, 2003, 22, 5907-5914.	2.6	283
254	Estimating hypoxic status in human tumors: A simulation using Eppendorf oxygen probe data in cervical cancer patients. International Journal of Radiation Oncology Biology Physics, 2003, 55, 1239-1246.	0.4	37
255	Positron emission tomography imaging of brain tumors. Neuroimaging Clinics of North America, 2003, 13, 717-739.	0.5	39
256	Influence of haemoglobin Concentration and peripheral muscle pO 2 on tumour oxygenation in advanced head and neck tumours. Radiotherapy and Oncology, 2003, 66, 71-74.	0.3	26
257	Radiotherapy and chemotherapy with or without carbogen and nicotinamide in inoperable biopsy-proven glioblastoma multiforme. Radiotherapy and Oncology, 2003, 67, 45-51.	0.3	19
258	Measurements of hypoxia using pimonidazole and polarographic oxygen-sensitive electrodes in human cervix carcinomas. Radiotherapy and Oncology, 2003, 67, 35-44.	0.3	140
259	Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. Radiotherapy and Oncology, 2003, 67, 3-15.	0.3	256
260	Radiotherapy with or without mitomycin c in the treatment of locally advanced head and neck cancer: results of the IAEA multicentre randomised trial. Radiotherapy and Oncology, 2003, 67, 17-26.	0.3	64

# 261	ARTICLE The importance of pre-treatment haemoglobin level in inoperablenon-small cell lung carcinoma treated with radical radiotherapy. Radiotherapy and Oncology, 2003, 67, 321-325.	IF 0.3	CITATIONS 30
262	Tumour oxygenation assessed by 18F-fluoromisonidazole PET and polarographic needle electrodes in human soft tissue tumours. Radiotherapy and Oncology, 2003, 67, 339-344.	0.3	114
263	The effect of anaemia on efficacy and normal tissue toxicity following radiotherapy for locally advanced squamous cell carcinoma of the head and neck. Radiotherapy and Oncology, 2003, 68, 113-122.	0.3	32
264	Modification of Radiation Response. Medical Radiology, 2003, , .	0.0	7
265	Correlation of Tumor Oxygen Dynamics with Radiation Response of the Dunning Prostate R3327-HI Tumor1. Radiation Research, 2003, 159, 621-631.	0.7	57
266	Increased locoregional blood flow in brain tumors after cervical spinal cord stimulation. Journal of Neurosurgery, 2003, 98, 1263-1270.	0.9	28
267	Targeted molecular mechanisms of epoetin alfa. Lung Cancer, 2003, 41, 133-145.	0.9	10
268	Prognostic significance of tumor oxygenation in humans. Cancer Letters, 2003, 195, 1-16.	3.2	259
269	Reduced expression of p27 is correlated with progression in precancerous lesions of the larynx. Auris Nasus Larynx, 2003, 30, 163-168.	0.5	18
270	The value of positron emission tomography for monitoring response to radiotherapy in head and neck cancer. Molecular Imaging and Biology, 2003, 5, 257-270.	1.3	37
271	Efficacy of cytotoxic agents used in the treatment of testicular germ cell tumours under normoxic and hypoxic conditions in vitro. British Journal of Cancer, 2003, 89, 2133-2139.	2.9	112
272	Overexpression of hypoxia-inducible-factor 1α(HIF-1α) in oesophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. British Journal of Cancer, 2003, 89, 1042-1047.	2.9	124
273	The role of functional and molecular imaging in cancer drug discovery and development. British Journal of Radiology, 2003, 76, S128-S138.	1.0	58
274	Ultrasound guided pO 2 measurement of breast cancer reoxygenation after neoadjuvant chemotherapy and hyperthermia treatment. International Journal of Hyperthermia, 2003, 19, 498-506.	1.1	34
275	Anemia before and during concurrent chemoradiotherapy in patients with cervical carcinoma: Effect on progression-free survival. International Journal of Gynecological Cancer, 2003, 13, 633-639.	1.2	25
276	Adjuvant Ozonetherapy in Advanced Head and Neck Tumors: A Comparative Study. Evidence-based Complementary and Alternative Medicine, 2004, 1, 321-325.	0.5	15
277	The relationship between temporal variation of hypoxia, polarographic measurements and predictions of tumour response to radiation. Physics in Medicine and Biology, 2004, 49, 4463-4475.	1.6	29
278	Current issues in the utility of 19 F nuclear magnetic resonance methodologies for the assessment of tumour hypoxia. Philosophical Transactions of the Royal Society B: Biological Sciences, 2004, 359, 987-996.	1.8	49

#	Article	IF	CITATIONS
279	Effect of cervical spinal cord stimulation on regional blood flow and oxygenation in advanced head and neck tumours. Annals of Oncology, 2004, 15, 802-807.	0.6	26
280	Effect of Radiation and Ibuprofen on Normoxic Renal Carcinoma Cells Overexpressing Hypoxia-Inducible Factors by Loss of von Hippel–Lindau Tumor Suppressor Gene Function. Clinical Cancer Research, 2004, 10, 4158-4164.	3.2	19
281	Approaches to Preserve Larynx Function in Locally Advanced Laryngeal and Hypopharyngeal Cancer. Oncology Research and Treatment, 2004, 27, 368-375.	0.8	6
282	Hypoxia-Inducible Factor 1α Expression as an Intrinsic Marker of Hypoxia. Clinical Cancer Research, 2004, 10, 8405-8412.	3.2	123
283	Evidence that involucrin, a marker for differentiation, is oxygen regulated in human squamous cell carcinomas. British Journal of Cancer, 2004, 90, 728-735.	2.9	58
284	Hypoxia and Anemia: Factors in Decreased Sensitivity to Radiation Therapy and Chemotherapy?. Oncologist, 2004, 9, 31-40.	1.9	314
285	Identification of Hypoxia-Regulated Proteins in Head and Neck Cancer by Proteomic and Tissue Array Profiling. Cancer Research, 2004, 64, 7302-7310.	0.4	36
286	Physiological mechanisms underlying heat-induced radiosensitization. International Journal of Hyperthermia, 2004, 20, 163-174.	1.1	86
287	Hypoxia and Photofrin Uptake in the Intraperitoneal Carcinomatosis and Sarcomatosis of Photodynamic Therapy Patients. Clinical Cancer Research, 2004, 10, 4630-4638.	3.2	57
288	Exploiting tumour hypoxia in cancer treatment. Nature Reviews Cancer, 2004, 4, 437-447.	12.8	2,406
289	In vivo evaluation of [18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography. British Journal of Cancer, 2004, 90, 2232-2242.	2.9	93
290	The human tumor microenvironment: invasive (needle) measurement of oxygen and interstitial fluid pressure. Seminars in Radiation Oncology, 2004, 14, 249-258.	1.0	140
291			
	The hypoxic tumor microenvironment and gene expression. Seminars in Radiation Oncology, 2004, 14, 207-214.	1.0	100
292	The hypoxic tumor microenvironment and gene expression. Seminars in Radiation Oncology, 2004, 14, 207-214. Strategies to overcome accelerated repopulation and hypoxia—what have we learned from clinical trials?. Seminars in Oncology, 2004, 31, 802-808.	1.0 0.8	100 28
292 293	The hypoxic tumor microenvironment and gene expression. Seminars in Radiation Oncology, 2004, 14, 207-214. Strategies to overcome accelerated repopulation and hypoxia— what have we learned from clinical trials?. Seminars in Oncology, 2004, 31, 802-808. Antioxidative Mikron�hrstoffe als Zusatzstoffe in der Onkologie. Onkologe, 2004, 10, 230-243.	1.0 0.8 0.7	100 28 1
292 293 294	The hypoxic tumor microenvironment and gene expression. Seminars in Radiation Oncology, 2004, 14, 207-214. Strategies to overcome accelerated repopulation and hypoxiaâ€" what have we learned from clinical trials?. Seminars in Oncology, 2004, 31, 802-808. Antioxidative Mikronïz¼/2hrstoffe als Zusatzstoffe in der Onkologie. Onkologe, 2004, 10, 230-243. Protocol of radiotherapy for glioblastoma according to the expression of HIF-1. Brain Tumor Pathology, 2004, 21, 1-6.	1.0 0.8 0.7 1.1	100 28 1 31
292 293 294 295	The hypoxic tumor microenvironment and gene expression. Seminars in Radiation Oncology, 2004, 14, 207-214. Strategies to overcome accelerated repopulation and hypoxiaâ€"what have we learned from clinical trials?. Seminars in Oncology, 2004, 31, 802-808. Antioxidative Mikron�/zhrstoffe als Zusatzstoffe in der Onkologie. Onkologe, 2004, 10, 230-243. Protocol of radiotherapy for glioblastoma according to the expression of HIF-1. Brain Tumor Pathology, 2004, 21, 1-6. Effects of texaphyrins on the oxygenation of EMT6 mouse mammary tumors. International Journal of Radiation Oncology Biology Physics, 2004, 58, 1570-1576.	1.0 0.8 0.7 1.1	100 28 1 31 31

#	Article	IF	CITATIONS
297	Effect of the Hypoxic Cell Sensitizer Isometronidazole on Local Control of Two Human Squamous Cell Carcinomas after Fractionated Irradiation. Strahlentherapie Und Onkologie, 2004, 180, 375-382.	1.0	17
298	Management of Anemia in Patients Undergoing Curative Radiotherapy. Strahlentherapie Und Onkologie, 2004, 180, 671-681.	1.0	33
299	Fluorinated tracers for imaging cancer with positron emission tomography. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 1182-206.	3.3	116
300	lodine-124-labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 117-128.	3.3	88
301	Molecular imaging in oncology by means of nuclear medicine: fact or fiction?. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 151-154.	3.3	1
302	Hypoxia-inducible factor-1? in non small cell lung cancer: Relation to growth factor, protease and apoptosis pathways. International Journal of Cancer, 2004, 111, 43-50.	2.3	153
303	Tumor R2* is a prognostic indicator of acute radiotherapeutic response in rodent tumors. Journal of Magnetic Resonance Imaging, 2004, 19, 482-488.	1.9	91
304	Clinical applications of EPR: overview and perspectives. NMR in Biomedicine, 2004, 17, 335-351.	1.6	133
305	Imaging perfusion and hypoxia with PET to predict radiotherapy response in head-and-neck cancer. International Journal of Radiation Oncology Biology Physics, 2004, 59, 971-982.	0.4	171
306	Low dose hyper-radiosensitivity in metastatic tumors. International Journal of Radiation Oncology Biology Physics, 2004, 59, 1190-1195.	0.4	63
307	Predicting the effect of temporal variations in po2 on tumor radiosensitivity. International Journal of Radiation Oncology Biology Physics, 2004, 59, 822-833.	0.4	47
308	Effect of RSR13, an allosteric hemoglobin modifier, on oxygenation in murine tumors: an in vivo electron paramagnetic resonance oximetry and bold MRI study. International Journal of Radiation Oncology Biology Physics, 2004, 59, 834-843.	0.4	34
309	Effects of nicotinamide and carbogen in different murine colon carcinomas: Immunohistochemical analysis of vascular architecture and microenvironmental parameters. International Journal of Radiation Oncology Biology Physics, 2004, 60, 310-321.	0.4	30
310	Optimization of the Auxiliary Ligand Shell of Cobalt(III)(8-hydroxyquinoline) Complexes as Model Hypoxia-Selective Radiation-Activated Prodrugs. Radiation Research, 2004, 162, 315-325.	0.7	39
311	Down-Regulation of Rad51 and Decreased Homologous Recombination in Hypoxic Cancer Cells. Molecular and Cellular Biology, 2004, 24, 8504-8518.	1.1	341
312	DNA-Targeted 1,2,4-Benzotriazine 1,4-Dioxides:  Potent Analogues of the Hypoxia-Selective Cytotoxin Tirapazamine. Journal of Medicinal Chemistry, 2004, 47, 475-488.	2.9	64
313	Investigation of thyroid, head, and neck cancers with PET. Radiologic Clinics of North America, 2004, 42, 1101-1111.	0.9	28
314	Tumor hypoxia is independent of hemoglobin and prognostic for loco-regional tumor control after primary radiotherapy in advanced head and neck cancer. Acta Oncológica, 2004, 43, 396-403.	0.8	135

ARTICLE IF CITATIONS A Novel Design Strategy for Stable Metal Complexes of Nitrogen Mustards as Bioreductive Prodrugs. 315 2.9 51 Journal of Medicinal Chemistry, 2004, 47, 5683-5689. Overexpression of Dimethylarginine Dimethylaminohydrolase Enhances Tumor Hypoxia: An Insight into 2.3 the Relationship of Hypoxía and Angiogenesis In Vivo. Neoplasia, 2004, 6, 401-411. Prognostic value of facilitative glucose transporter Glut-1 in oral squamous cell carcinomas treated 317 1.3 81 by surgical resection. European Journal of Cancer, 2004, 40, 503-507. Hypoxia in Renal Disease with Proteinuria and/or Glomerular Hypertension. American Journal of 318 1.9 Páthology, 2004, 165, 1979-1992. Functional imaging of intratumoral hypoxia. Molecular Imaging and Biology, 2004, 6, 291-305. 319 1.393 Utility of 19F MRS detection of the hypoxic cell marker EF5 to assess cellular hypoxia in solid tumors. Radiotherapy and Oncology, 2004, 73, 359-366. 0.3 Radiotoxicity on bone marrow after 89Sr therapy radiosensitized by nicotinamide and carbogen in 321 0.5 0 mice. Nuclear Medicine Communications, 2004, 25, 701-704. Carbonic anhydrase IX, a marker of hypoxia: Correlation with clinical outcome in transitional cell 1.2 carcinoma of the bladder. Oncology Reports, 2004, 11, 1005. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study 323 featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in 0.4 183 the R3327-AT and FaDu rat tumor models. International Journal of Radiation Oncology Biology Physics, 2005, 61, 1493-1502 Effect of intratumoral heterogeneity in oxygenation status on FMISO PET, autoradiography, and 324 electrode Po2 measurements in murine tumors. International Journal of Radiation Oncology Biology 0.4 Physics, 2005, 62, 854-861. The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation 325 response in large, advanced tumors. International Journal of Radiation Oncology Biology Physics, 0.4 64 2005, 62, 846-853. Hypoxic cell turnover in different solid tumor lines. International Journal of Radiation Oncology 0.4 79 Biology Physics, 2005, 62, 1157-1168. Anemia, tumor hypoxemia, and the cancer patient. International Journal of Radiation Oncology 327 0.4 133 Biology Physics, 2005, 63, 25-36. Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission 1.3 122 tomography. BJU International, 2005, 96, 540-546. The impact of anaemia on outcome in cancer. International Journal of Laboratory Hematology, 2005, 329 0.2 46 27, 1-13. Genetic instability and the tumor microenvironment: towards the concept of microenvironment-induced mutagenesis. Mutation Research - Fundamental and Molecular Mechanisms 146 of Mutagenesis, 2005, 569, 75-85 Kinetic analysis of dynamic 18F-fluoromisonidazole PET correlates with radiation treatment outcome 331 1.1 156in head-and-neck cancer. BMC Cancer, 2005, 5, 152. Hypoxia in head and neck cancer: How much, how important?. Head and Neck, 2005, 27, 622-638.

#	Article	IF	CITATIONS
333	Radiotherapy alone or combined with carbogen breathing for squamous cell carcinoma of the head and neck. Cancer, 2005, 104, 332-337.	2.0	29
334	Absolute oxygen tension (pO2) in murine fatty and muscle tissue as determined by EPR. Magnetic Resonance in Medicine, 2005, 54, 1530-1535.	1.9	78
335	Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 1384-1391.	3.3	135
336	Blood Transfusion Requirements for Patients With Sarcomas Undergoing Combined Radio- and Chemotherapy. Sarcoma, 2005, 9, 119-125.	0.7	Ο
337	The effects of hypoxia on the theoretical modelling of tumour control probability. Acta Oncológica, 2005, 44, 563-571.	0.8	38
338	Hyperthermic Enhancement of Tumor Radiosensitization Strategies. Immunological Investigations, 2005, 34, 343-359.	1.0	22
339	Large-Scale Analysis of Genes that Alter Sensitivity to the Anticancer Drug Tirapazamine inSaccharomyces cerevisiae. Molecular Pharmacology, 2005, 68, 1365-1375.	1.0	22
340	A kinetic model for dynamic [18F]-Fmiso PET data to analyse tumour hypoxia. Physics in Medicine and Biology, 2005, 50, 2209-2224.	1.6	159
341	Conversion of polarographic electrode measurements—a computer based approach. Physics in Medicine and Biology, 2005, 50, 4581-4591.	1.6	2
342	DNA damage induced by a quinoxaline 1,4-di-N-oxide derivative (hypoxic selective agent) in Caco-2 cells evaluated by the comet assay. Mutagenesis, 2005, 20, 165-171.	1.0	20
343	Oxaliplatin combined with infusional 5-fluorouracil and concomitant radiotherapy in inoperable and metastatic rectal cancer: a phase I trial. British Journal of Cancer, 2005, 92, 655-661.	2.9	33
344	Oxygen distribution in murine tumors: characterization using oxygen-dependent quenching of phosphorescence. Journal of Applied Physiology, 2005, 98, 1503-1510.	1.2	90
345	Microenvironmental Effects on Tumour Progression and Metastasis. , 2005, , 1-22.		2
346	Hypoxia-regulated glucose transporter Glut-1 may influence chemosensitivity to some alkylating agents: Results of EORTC (First Translational Award) study of the relevance of tumour hypoxia to the outcome of chemotherapy in human tumour-derived xenografts. International Journal of Oncology, 2005, 26, 1477-84.	1.4	17
347	A Noninvasive Approach for Assessing Tumor Hypoxia in Xenografts: Developing a Urinary Marker for Hypoxia. Cancer Research, 2005, 65, 6151-6158.	0.4	10
348	Measurement of Hypoxia-related Parameters in Bronchial Mucosa by Use of Optical Spectroscopy. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 1178-1184.	2.5	54
349	Combination therapy with bacteria and angiogenesis inhibitors: Strangling cancer without mercy. Cancer Biology and Therapy, 2005, 4, 846-847.	1.5	4
350	The hypoxic proteome is influenced by gene-specific changes in mRNA translation. Radiotherapy and Oncology, 2005, 76, 177-186.	0.3	105

#	Article	IF	CITATIONS
351	Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiotherapy and Oncology, 2005, 77, 18-24.	0.3	867
352	Current Imaging Paradigms in Radiation Oncology. Radiation Research, 2005, 163, 1-25.	0.7	62
353	Imaging hypoxia and angiogenesis in tumors. Radiologic Clinics of North America, 2005, 43, 169-187.	0.9	138
354	Relationship between radiobiological hypoxia in a C3H mouse mammary carcinoma and osteopontin levels in mouse serum. International Journal of Radiation Biology, 2005, 81, 937-944.	1.0	18
355	Hypoxia-Induced Phosphorylation of Chk2 in an Ataxia Telangiectasia Mutated–Dependent Manner. Cancer Research, 2005, 65, 10734-10741.	0.4	85
356	Preoperative radiochemotherapy and radical resection for stages II–IV oral and oropharyngeal cancer: outcome of 222 patients. International Journal of Oral and Maxillofacial Surgery, 2005, 34, 143-148.	0.7	29
357	Preoperative radiochemotherapy and radical resection for stages II to IV oral and oropharyngeal cancer: grade of regression as crucial prognostic factor. International Journal of Oral and Maxillofacial Surgery, 2005, 34, 262-267.	0.7	24
358	Cell line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSM. Nuclear Medicine and Biology, 2005, 32, 623-630.	0.3	98
359	Efaproxiral: A Radiation Enhancer Used in Brain Metastases from Breast Cancer. Annals of Pharmacotherapy, 2005, 39, 2038-2045.	0.9	1
360	Tumour Oxygenation: The Importance of Hypoxia, Anemia, and Angiogenesis in Radiation Therapy. Journal of Medical Imaging and Radiation Sciences, 2005, 36, 21-33.	0.1	2
361	Erythropoietin Biology in Cancer. Clinical Cancer Research, 2006, 12, 332-339.	3.2	201
362	Cancer Drug Resistance. , 2006, , .		21
364	A model to simulate tumour oxygenation and dynamic [18F]-Fmiso PET data. Physics in Medicine and Biology, 2006, 51, 5859-5873.	1.6	76
365	The Effect of Darbepoetin Alfa on Growth, Oxygenation and Radioresponsiveness of a Breast Adenocarcinoma. Radiation Research, 2006, 165, 192-201.	0.7	12
366	Reassessment of the role of induction chemotherapy for head and neck cancer. Lancet Oncology, The, 2006, 7, 565-574.	5.1	53
367	Hypoxia induced by benign intestinal epithelial cells is associated with cyclooxygenase-2 expression in stromal cells through AP-1-dependent pathway. Oncogene, 2006, 25, 3277-3285.	2.6	8
368	Tirapazamine causes vascular dysfunction in HCT-116 tumour xenografts. Radiotherapy and Oncology, 2006, 78, 138-145.	0.3	17
369	The prognostic value of pimonidazole and tumour pO2 in human cervix carcinomas after radiation therapy: A prospective international multi-center study. Radiotherapy and Oncology, 2006, 80, 123-131.	0.3	98

#	Article	IF	CITATIONS
370	Imaging hypoxia after oxygenation-modification: Comparing [18F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors. Radiotherapy and Oncology, 2006, 80, 157-164.	0.3	72
371	Hypoxia in relation to vasculature and proliferation in liver metastases in patients with colorectal cancer. International Journal of Radiation Oncology Biology Physics, 2006, 64, 473-482.	0.4	68
372	Hypoxia in human colorectal adenocarcinoma: Comparison between extrinsic and potential intrinsic hypoxia markers. International Journal of Radiation Oncology Biology Physics, 2006, 65, 246-254.	0.4	64
373	Clinical Significance of Immunohistochemical Expression of Hypoxia-Inducible Factor–1α as a Prognostic Marker in Rectal Adenocarcinoma. Clinical Colorectal Cancer, 2006, 5, 350-353.	1.0	26
374	Patterns of tumor oxygenation and their influence on the cellular hypoxic response and hypoxia-directed therapies. Drug Resistance Updates, 2006, 9, 185-197.	6.5	37
375	Combined Modality Approaches Using Vasculature-disrupting Agents. , 2006, , 123-136.		7
376	Tumor Vasculature: a Target for Anticancer Therapies. , 2006, , 1-8.		11
377	PET-Based Biological Imaging for Radiation Therapy Treatment Planning. Critical Reviews in Eukaryotic Gene Expression, 2006, 16, 61-102.	0.4	15
379	Erythropoietin or Darbepoetin for patients with cancer. , 2006, , CD003407.		106
380	Tumor Hypoxia and Prognosis in Human Gliomas. Cancer Journal (Sudbury, Mass), 2006, 12, 451-454.	1.0	3
380 381	Tumor Hypoxia and Prognosis in Human Gliomas. Cancer Journal (Sudbury, Mass), 2006, 12, 451-454. Oxygenated and reoxygenated tumors show better local control in radiation therapy for cervical cancer. International Journal of Gynecological Cancer, 2006, 16, 306-311.	1.0 1.2	3 35
380 381 382	Tumor Hypoxia and Prognosis in Human Gliomas. Cancer Journal (Sudbury, Mass), 2006, 12, 451-454. Oxygenated and reoxygenated tumors show better local control in radiation therapy for cervical cancer. International Journal of Gynecological Cancer, 2006, 16, 306-311. Prognostic Value of Haemoglobin Levels During Concurrent Radio-chemotherapy in the Treatment of Oesophageal Cancer. Clinical Oncology, 2006, 18, 139-144.	1.0 1.2 0.6	3 35 23
380 381 382 383	Tumor Hypoxia and Prognosis in Human Gliomas. Cancer Journal (Sudbury, Mass), 2006, 12, 451-454. Oxygenated and reoxygenated tumors show better local control in radiation therapy for cervical cancer. International Journal of Gynecological Cancer, 2006, 16, 306-311. Prognostic Value of Haemoglobin Levels During Concurrent Radio-chemotherapy in the Treatment of Oesophageal Cancer. Clinical Oncology, 2006, 18, 139-144. Prospective study on stereotactic radiotherapy of limited-stage non–small-cell lung cancer. International Journal of Radiation Oncology Biology Physics, 2006, 66, S128-S135.	1.0 1.2 0.6 0.4	3 35 23 78
380 381 382 383 383	Tumor Hypoxia and Prognosis in Human Gliomas. Cancer Journal (Sudbury, Mass), 2006, 12, 451-454. Oxygenated and reoxygenated tumors show better local control in radiation therapy for cervical cancer. International Journal of Gynecological Cancer, 2006, 16, 306-311. Prognostic Value of Haemoglobin Levels During Concurrent Radio-chemotherapy in the Treatment of Oesophageal Cancer. Clinical Oncology, 2006, 18, 139-144. Prospective study on stereotactic radiotherapy of limited-stage non–small-cell lung cancer. International Journal of Radiation Oncology Biology Physics, 2006, 66, S128-S135. Advances in methods for assessing tumor hypoxia in vivo: Implications for treatment planning. Cancer and Metastasis Reviews, 2006, 25, 469-480.	1.0 1.2 0.6 0.4 2.7	3 35 23 78 33
380 381 382 383 383 384	Tumor Hypoxia and Prognosis in Human Gliomas. Cancer Journal (Sudbury, Mass), 2006, 12, 451-454. Oxygenated and reoxygenated tumors show better local control in radiation therapy for cervical cancer. International Journal of Gynecological Cancer, 2006, 16, 306-311. Prognostic Value of Haemoglobin Levels During Concurrent Radio-chemotherapy in the Treatment of Oesophageal Cancer. Clinical Oncology, 2006, 18, 139-144. Prospective study on stereotactic radiotherapy of limited-stage nonâ€"small-cell lung cancer. International Journal of Radiation Oncology Biology Physics, 2006, 66, S128-S135. Advances in methods for assessing tumor hypoxia in vivo: Implications for treatment planning. Cancer and Metastasis Reviews, 2006, 25, 469-480. Expression of hypoxia-inducible factor (HIF)-1î± as a biomarker of outcome in soft-tissue sarcomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 449, 673-681.	1.0 1.2 0.6 0.4 2.7 1.4	3 35 23 78 33 51
380 381 382 383 383 385	Tumor Hypoxia and Prognosis in Human Gliomas. Cancer Journal (Sudbury, Mass), 2006, 12, 451-454. Oxygenated and reoxygenated tumors show better local control in radiation therapy for cervical cancer. International Journal of Cynecological Cancer, 2006, 16, 306-311. Prognostic Value of Haemoglobin Levels During Concurrent Radio-chemotherapy in the Treatment of Oesophageal Cancer. Clinical Oncology, 2006, 18, 139-144. Prospective study on stereotactic radiotherapy of limited-stage non–small-cell lung cancer. International Journal of Radiation Oncology Biology Physics, 2006, 66, S128-S135. Advances in methods for assessing tumor hypoxia in vivo: Implications for treatment planning. Cancer and Metastasis Reviews, 2006, 25, 469-480. Expression of hypoxia-inducible factor (HIF)-11± as a biomarker of outcome in soft-tissue sarcomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 449, 673-681. Influence of Pretreatment Polarographically Measured Oxygenation Levels in Spontaneous Canine Tumors Treated with Radiation Therapy. Strahlentherapie Und Onkologie, 2006, 182, 518-524.	1.0 1.2 0.6 0.4 2.7 1.4 1.0	3 35 23 78 33 51 13
380 381 382 383 383 384 385 385	Tumor Hypoxia and Prognosis in Human Gliomas. Cancer Journal (Sudbury, Mass), 2006, 12, 451-454. Oxygenated and reoxygenated tumors show better local control in radiation therapy for cervical cancer. International Journal of Gynecological Cancer, 2006, 16, 306-311. Prognostic Value of Haemoglobin Levels During Concurrent Radio-chemotherapy in the Treatment of Oesophageal Cancer. Clinical Oncology, 2006, 18, 139-144. Prospective study on stereotactic radiotherapy of limited-stage non–small-cell lung cancer. International Journal of Radiation Oncology Biology Physics, 2006, 66, S128-S135. Advances in methods for assessing tumor hypoxia in vivo: Implications for treatment planning. Cancer and Metastasis Reviews, 2006, 25, 469-480. Expression of hypoxia-inducible factor (HIF)-1î± as a biomarker of outcome in soft-tissue sarcomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 449, 673-681. Influence of Pretreatment Polarographically Measured Oxygenation Levels in Spontaneous Canine Tumors Treated with Radiation Therapy. Strahlentherapie Und Onkologie, 2006, 182, 518-524. Impact of Hemoglobin Levels on Tumor Oxygenation: the Higher, the Better?. Strahlentherapie Und Onkologie, 2006, 182, 63-71.	1.0 1.2 0.6 0.4 2.7 1.4 1.0	3 35 23 78 33 51 13 120

#	Article	IF	CITATIONS
389	Novel Therapeutic Targets: The PERKs of Inhibiting the Integrated Stress Response. Cell Cycle, 2006, 5, 2874-2877.	1.3	11
390	Effect of Reoxygenation on the Hypoxia-Induced Up-Regulation of Serine Protease Inhibitor PAI-1 in Head and Neck Cancer Cells. Oncology, 2006, 71, 282-291.	0.9	14
391	Dose escalation to combat hypoxia in prostate cancer: a radiobiological study on clinical data. British Journal of Radiology, 2006, 79, 905-911.	1.0	35
393	Hypoxia in head and neck cancer. British Journal of Radiology, 2006, 79, 791-798.	1.0	76
394	Expression of Erythropoietin and Erythropoietin Receptor in Cervical Cancer and Relationship to Survival, Hypoxia, and Apoptosis. Clinical Cancer Research, 2006, 12, 6894-6900.	3.2	44
395	Tumor Hypoxia Imaging: Fig. 1 Clinical Cancer Research, 2006, 12, 5260-5264.	3.2	45
396	Carbon Beam Therapy Overcomes the Radiation Resistance of Uterine Cervical Cancer Originating from Hypoxia. Clinical Cancer Research, 2006, 12, 2185-2190.	3.2	126
397	Effects of oxygen on intrinsic radiation sensitivity: A test of the relationship between aerobic and	1.6	117
398	Adapting radiotherapy to hypoxic tumours. Physics in Medicine and Biology, 2006, 51, 4903-4921.	1.6	70
399	Pathophysiologic Effects of Vascular-Targeting Agents and the Implications for Combination with Conventional Therapies. Cancer Research, 2006, 66, 11520-11539.	0.4	237
400	Analysis of Prognostic Variables among Patients with Locally Advanced Head and Neck Cancer Treated with Late Chemo-Intensification Protocol: Impact of Nodal Density and Total Tumor Volume. Japanese Journal of Clinical Oncology, 2006, 36, 537-546.	0.6	16
401	Expression of the Hypoxia Marker Carbonic Anhydrase 9 Is Associated with Anaplastic Phenotypes in Meningiomas. Clinical Cancer Research, 2007, 13, 68-75.	3.2	30
402	Detecting changes in tumor hypoxia with carbonic anhydrase IX and pimonidazole. Cancer Biology and Therapy, 2007, 6, 70-75.	1.5	38
403	The Effects of Efaproxynâ,,¢ (Efaproxiral) on Subcutaneous RIF-1 Tumor Oxygenation and Enhancement of Radiotherapy-Mediated Inhibition of Tumor Growth in Mice. Radiation Research, 2007, 168, 218-225.	0.7	30
404	Detection and Characterization of Tumor Hypoxia Using pO2 Histography. Antioxidants and Redox Signaling, 2007, 9, 1221-1236.	2.5	628
405	Multi-Detector Computed Tomography in Oncology. , 0, , .		6
406	Mechanism of Action and Preclinical Antitumor Activity of the Novel Hypoxia-Activated DNA Cross-Linking Agent PR-104. Clinical Cancer Research, 2007, 13, 3922-3932.	3.2	208
407	Lack of Apoptotic Protease Activating Factor-1 Expression and Resistance to Hypoxia-Induced Apoptosis in Cervical Cancer. Clinical Cancer Research, 2007, 13, 1149-1153.	3.2	7

#	Article	IF	CITATIONS
408	Visualization of Hypoxia in Microscopic Tumors by Immunofluorescent Microscopy. Cancer Research, 2007, 67, 7646-7653.	0.4	111
409	Metallothionein is up-regulated under hypoxia and promotes the survival of human prostate cancer cells. Oncology Reports, 2007, 18, 1145.	1.2	20
410	The influence of tumor oxygenation on hypoxia imaging in murine squamous cell carcinoma using [64Cu]Cu-ATSM or [18F]Fluoromisonidazole positron emission tomography. International Journal of Oncology, 2007, 30, 873.	1.4	15
411	Hemodynamic responses to antivascular therapy and ionizing radiation assessed by diffuse optical spectroscopies. Optics Express, 2007, 15, 15507.	1.7	51
412	Interrelation of directly measured oxygenation levels, erythropoietin and erythropoietin receptor expression in spontaneous canine tumours. European Journal of Cancer, 2007, 43, 963-967.	1.3	4
413	Genome-wide expression analysis using microarray identified complex signaling pathways modulated by hypoxia in nasopharyngeal carcinoma. Cancer Letters, 2007, 253, 74-88.	3.2	50
414	Differential risk assessments from five hypoxia specific assays: The basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients. Radiotherapy and Oncology, 2007, 83, 389-397.	0.3	80
415	Hypoxia Positron Emission Tomography Imaging With 18F-Fluoromisonidazole. Seminars in Nuclear Medicine, 2007, 37, 451-461.	2.5	274
416	Repetitive Tissue pO2 Measurements by Electron Paramagnetic Resonance Oximetry: Current Status and Future Potential for Experimental and Clinical Studies. Antioxidants and Redox Signaling, 2007, 9, 1169-1182.	2.5	121
417	Tumor Hypoxia in Cancer Therapy. Methods in Enzymology, 2007, 435, 295-321.	0.4	254
418	The Potential Role of Intrinsic Hypoxia Markers as Prognostic Variables in Cancer. Antioxidants and Redox Signaling, 2007, 9, 1237-1294.	2.5	81
419	Bystander Effects of Bioreductive Drugs: Potential for Exploiting Pathological Tumor Hypoxia with Dinitrobenzamide Mustards. Radiation Research, 2007, 167, 625-636.	0.7	61
420	Pharmacokinetic/Pharmacodynamic Model-Guided Identification of Hypoxia-Selective 1,2,4-Benzotriazine 1,4-Dioxides with Antitumor Activity: The Role of Extravascular Transport. Journal of Medicinal Chemistry, 2007, 50, 6392-6404.	2.9	40
421	Hypoxia-Selective 3-Alkyl 1,2,4-Benzotriazine 1,4-Dioxides: The Influence of Hydrogen Bond Donors on Extravascular Transport and Antitumor Activity. Journal of Medicinal Chemistry, 2007, 50, 6654-6664.	2.9	43
422	Hypoxic Regulation of Glucose Transport, Anaerobic Metabolism and Angiogenesis in Cancer: Novel Pathways and Targets for Anticancer Therapeutics. Chemotherapy, 2007, 53, 233-256.	0.8	299
423	Targeting tumors with hypoxia-activated cytotoxins. Frontiers in Bioscience - Landmark, 2007, 12, 3483.	3.0	54
424	Hypoxia and prognosis: the oxygen tension mounts. Frontiers in Bioscience - Landmark, 2007, 12, 3502.	3.0	8
425	3â€fâ€fRadiotherapy predictive assays. , 2007, , 35-50.		1

#	Article	IF	CITATIONS
426	8â€fâ€fThe oxygen effect. , 2007, , 138-157.		5
427	10â€fâ€fInter-tumour heterogeneity and tumour control. , 2007, , 169-195.		4
428	Multispectral quantification of tissue types in a RIF-1 tumor model with histological validation. Part I. Magnetic Resonance in Medicine, 2007, 57, 501-512.	1.9	37
429	Vascular Damaging Agents. Clinical Oncology, 2007, 19, 443-456.	0.6	122
430	Correlation of radiation response with tumor oxygenation in the Dunning prostate R3327-AT1 tumor. International Journal of Radiation Oncology Biology Physics, 2007, 67, 1179-1186.	0.4	47
431	Hypoxia Dose Painting by Numbers: A Planning Study. International Journal of Radiation Oncology Biology Physics, 2007, 68, 291-300.	0.4	269
432	A Model of Reoxygenation Dynamics of Head-And-Neck Tumors Based on Serial 18F-Fluoromisonidazole Positron Emission Tomography Investigations. International Journal of Radiation Oncology Biology Physics, 2007, 68, 515-521.	0.4	76
433	Expression and Prognostic Significance of a Panel of Tissue Hypoxia Markers in Head-and-Neck Squamous Cell Carcinomas. International Journal of Radiation Oncology Biology Physics, 2007, 69, 167-175.	0.4	111
434	Oxygen Dependence and Extravascular Transport of Hypoxia-Activated Prodrugs: Comparison of the Dinitrobenzamide Mustard PR-104A and Tirapazamine. International Journal of Radiation Oncology Biology Physics, 2007, 69, 560-571.	0.4	66
435	Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer. British Journal of Cancer, 2007, 96, 104-109.	2.9	184
436	Reduction rate of lymph node metastasis as a significant prognostic factor in esophageal cancer patients treated with neoadjuvant chemoradiation therapy. Ecological Management and Restoration, 2007, 20, 94-101.	0.2	8
437	Induction of plasminogen activator inhibitor type-1 (PAI-1) by hypoxia and irradiation in human head and neck carcinoma cell lines. BMC Cancer, 2007, 7, 143.	1.1	17
438	Oxygen sensing and the DNA-damage response. Current Opinion in Cell Biology, 2007, 19, 680-684.	2.6	46
439	Tumor hypoxia and expression of c-met in cervical cancer. Gynecologic Oncology, 2007, 104, 181-185.	0.6	16
440	Anemia correction in malignancy management: Threat or opportunity?. Gynecologic Oncology, 2007, 105, 517-529.	0.6	20
441	Simultaneous application of the vascular endothelial growth factor (VEGF) receptor inhibitor PTK787/ZK 222584 and ionizing radiation does not further reduce the growth of canine oral melanoma xenografts in nude mice. Veterinary Journal, 2007, 173, 564-570.	0.6	3
442	Determination of tumour hypoxia with the PET tracer [18F]EF3: improvement of the tumour-to-background ratio in a mouse tumour model. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 1348-1354.	3.3	20
443	Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer and Metastasis Reviews, 2007, 26, 241-248.	2.7	364

#	Article	IF	CITATIONS
445	Versatile Nitro-Fluorophore as Highly Effective Sensor for Hypoxic Tumor Cells: Design, Imaging and Evaluation. Journal of Fluorescence, 2008, 18, 591-597.	1.3	27
446	FDG uptake, a surrogate of tumour hypoxia?. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1544-1549.	3.3	84
447	Cellular uptake of PET tracers of glucose metabolism and hypoxia and their linkage. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 2294-2303.	3.3	104
448	Neoadjuvant Radiochemotherapy and Radical Resection for Advanced Squamous Cell Carcinoma of the Oral Cavity. Strahlentherapie Und Onkologie, 2008, 184, 23-29.	1.0	46
450	Squamous-cell Carcinoma of the Anal Canal: Predictors of Treatment Outcome. Diseases of the Colon and Rectum, 2008, 51, 147-153.	0.7	100
451	Tumor Hypoxia Detected by Positron Emission Tomography with 60Cu-ATSM as a Predictor of Response and Survival in Patients Undergoing Neoadjuvant Chemoradiotherapy for Rectal Carcinoma: A Pilot Study. Diseases of the Colon and Rectum, 2008, 51, 1641-1648.	0.7	151
452	PXâ€478, an inhibitor of hypoxiaâ€inducible factorâ€lα, enhances radiosensitivity of prostate carcinoma cells. International Journal of Cancer, 2008, 123, 2430-2437.	2.3	95
453	Hypoxia Inducible Factor-1α and Vascular Endothelial Growth Factor Expression are Associated with a Poor Prognosis in Patients with Nasopharyngeal Carcinoma Receiving Radiotherapy with Carbogen and Nicotinamide. Clinical Oncology, 2008, 20, 606-612.	0.6	45
455	The Influence of Changes in Tumor Hypoxia on Dose-Painting Treatment Plans Based on 18F-FMISO Positron Emission Tomography. International Journal of Radiation Oncology Biology Physics, 2008, 70, 1219-1228.	0.4	168
456	Tricyclic [1,2,4]Triazine 1,4-Dioxides As Hypoxia Selective Cytotoxins. Journal of Medicinal Chemistry, 2008, 51, 6853-6865.	2.9	66
457	Impact of hemoglobin level on survival in definitive chemoradiotherapy for T4/M1 lymph node esophageal cancer. Ecological Management and Restoration, 2008, 21, 195-200.	0.2	21
458	From Cellular to High-Throughput Predictive Assays in Radiation Oncology: Challenges and Opportunities. Seminars in Radiation Oncology, 2008, 18, 75-88.	1.0	45
459	Molecular Imaging II. Handbook of Experimental Pharmacology, 2008, , .	0.9	2
460	[64Cu]diacetyl-bis(N4-methyl-thiosemicarbazone) — a radiotracer for tumor hypoxia. Nuclear Medicine and Biology, 2008, 35, 393-400.	0.3	33
461	Hypoxia in microscopic tumors. Cancer Letters, 2008, 264, 172-180.	3.2	60
462	Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treatment Reviews, 2008, 34, 592-602.	3.4	381
463	The role of hypoxia in canine cancer. Veterinary and Comparative Oncology, 2008, 6, 213-223.	0.8	9
464	An imaging-based tumour growth and treatment response model: investigating the effect of tumour oxygenation on radiation therapy response. Physics in Medicine and Biology, 2008, 53, 4471-4488.	1.6	64

#	Article	IF	CITATIONS
465	Tissue oxygenation in a murine SCC VII tumor after X-ray irradiation as determined by EPR spectroscopy. Radiotherapy and Oncology, 2008, 86, 354-360.	0.3	24
466	Enhanced local tumour control after single or fractionated radiation treatment using the hypoxic cell radiosensitizer doranidazole. Radiotherapy and Oncology, 2008, 87, 331-338.	0.3	16
467	[18F]‣abeled PET and PET/CT Compounds in Oncology. , 2008, , 141-196.		2
468	Lack of Hypoxic Response in Uterine Leiomyomas despite Severe Tissue Hypoxia. Cancer Research, 2008, 68, 4719-4726.	0.4	85
469	Biological image-guided radiotherapy in rectal cancer: Is there a role for FMISO or FLT, next to FDG?. Acta Oncológica, 2008, 47, 1237-1248.	0.8	76
470	18F-EF5: A New PET Tracer for Imaging Hypoxia in Head and Neck Cancer. Journal of Nuclear Medicine, 2008, 49, 1944-1951.	2.8	182
471	In Vitro and In Vivo Evaluations of a Hydrophilic ⁶⁴ Cu-Bis(Thiosemicarbazonato)–Glucose Conjugate for Hypoxia Imaging. Journal of Nuclear Medicine, 2008, 49, 1862-1868.	2.8	51
472	Molecular Imaging: Reporter Gene Imaging. Handbook of Experimental Pharmacology, 2008, , 167-223.	0.9	45
473	The impact of hypoxia on the activity of lactate dehydrogenase in two different pre-clinical tumour models. Acta Oncológica, 2008, 47, 941-947.	0.8	22
474	Plasma Osteopontin, Hypoxia, and Response to Radiotherapy in Nasopharyngeal Cancer. Clinical Cancer Research, 2008, 14, 7080-7087.	3.2	35
476	Efficient Monte Carlo modelling of individual tumour cell propagation for hypoxic head and neck cancer. Physics in Medicine and Biology, 2008, 53, 4489-4507.	1.6	18
477	Imaging and Analytical Methods as Applied to the Evaluation of Vasculature and Hypoxia in Human Brain Tumors. Radiation Research, 2008, 170, 677-690.	0.7	48
478	Vascular oxygen content and the tissue oxygenation-A theoretical analysis. Medical Physics, 2008, 35, 539-545.	1.6	21
479	Vascular endothelial growth factor is an autocrine survival factor for breast tumour cells under hypoxia. International Journal of Oncology, 2008, , .	1.4	22
480	Measurement of hypoxia using invasive oxygen-sensitive electrode, pimonidazole binding and 18F-FDG uptake in anaemic or erythropoietin-treated mice bearing human glioma xenografts. International Journal of Oncology, 0, , .	1.4	3
481	Erythropoietin in Cancer: An Update. Current Molecular Medicine, 2008, 8, 481-491.	0.6	21
482	Elevated CAIX Expression is Associated with an Increased Risk of Distant Failure in Early-Stage Cervical Cancer. Biomarker Insights, 2008, 3, BMI.S570.	1.0	30
484	Small-Molecule Activation of p53 Blocks Hypoxia-Inducible Factor 1α and Vascular Endothelial Growth Factor Expression In Vivo and Leads to Tumor Cell Apoptosis in Normoxia and Hypoxia. Molecular and Cellular Biology, 2009, 29, 2243-2253.	1.1	89

#	Article	IF	CITATIONS
485	Carbogen breathing increases prostate cancer oxygenation: a translational MRI study in murine xenografts and humans. British Journal of Cancer, 2009, 100, 644-648.	2.9	56
486	Hypoxia Enhances the Replication of Oncolytic Herpes Simplex Virus. Molecular Therapy, 2009, 17, 51-56.	3.7	64
487	Expression of the cellular oxygen sensor PHD2 (EGLN-1) predicts radiation sensitivity in squamous cell cancer of the head and neck. International Journal of Radiation Biology, 2009, 85, 900-908.	1.0	9
488	Complementary but Distinct Roles for MRI and ¹⁸ F-Fluoromisonidazole PET in the Assessment of Human Glioblastomas. Journal of Nuclear Medicine, 2009, 50, 36-44.	2.8	137
490	Increase in gene dosage is a mechanism of HIFâ€1α constitutive expression in head and neck squamous cell carcinomas. Genes Chromosomes and Cancer, 2009, 48, 441-454.	1.5	18
491	Molecular imaging of hypoxia with radiolabelled agents. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1674-1686.	3.3	190
492	A phase I study of the nitroimidazole hypoxia marker SR4554 using 19F magnetic resonance spectroscopy. British Journal of Cancer, 2009, 101, 1860-1868.	2.9	34
493	Expression of the cellular oxygen sensor PHD2 (EGLN-1) predicts radiation sensitivity in squamous cell cancer of the head and neck. International Journal of Radiation Biology, 2009, 85, 900-908.	1.0	14
494	On the sensitivity of IMRT dose optimization to the mathematical form of a biological imaging-based prescription function. Physics in Medicine and Biology, 2009, 54, 1483-1501.	1.6	57
497	Phase II Study of Nitric Oxide Donor for Men With Increasing Prostate-specific Antigen Level After Surgery or Radiotherapy for Prostate Cancer. Urology, 2009, 74, 878-883.	0.5	92
498	Prognostic significance of angiogenesis in surgically treated supraglottic squamous cell carcinomas of the larynx. Acta Otorrinolaringologica (English Edition), 2009, 60, 272-277.	0.1	5
499	The radiation response of cells from 9L gliosarcoma tumours is correlated with [F18]-EF5 uptake. International Journal of Radiation Biology, 2009, 85, 1137-1147.	1.0	21
500	Evaluation of a compartmental model for estimating tumor hypoxia via FMISO dynamic PET imaging. Physics in Medicine and Biology, 2009, 54, 3083-3099.	1.6	61
501	Proteins upregulated by mild and severe hypoxia in squamous cell carcinomas in vitro identified by proteomics. Radiotherapy and Oncology, 2009, 92, 443-449.	0.3	35
502	Can hypoxia-PET map hypoxic cell density heterogeneity accurately in an animal tumor model at a clinically obtainable image contrast?. Radiotherapy and Oncology, 2009, 92, 429-436.	0.3	50
503	Modeling acute and chronic hypoxia using serial images of PET. Medical Physics, 2009, 36, 4400-4408.	1.6	33
504	ATF4, an ER Stress and Hypoxia-Inducible Transcription Factor and its Potential Role in Hypoxia Tolerance and Tumorigenesis. Current Molecular Medicine, 2009, 9, 411-416.	0.6	105
505	Current Advancement in Radiation Therapy for Uterine Cervical Cancer. Journal of Radiation Research, 2010, 51, 1-8.	0.8	43

#	Article	IF	CITATIONS
506	Biodistribution and dosimetry of 18F-EF5 in cancer patients with preliminary comparison of 18F-EF5 uptake versus EF5 binding in human glioblastoma. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 2048-2059.	3.3	55
507	Genome-wide identification and annotation of HIF-1α binding sites in two cell lines using massively parallel sequencing. The HUGO Journal, 2010, 4, 35-48.	4.1	43
508	Radiotherapy versus radiochemotherapy with cisplatin in treatment of cervical cancer. Medical Oncology, 2010, 27, 1-8.	1.2	10
509	Focal dose escalation using FDG-PET-guided intensity-modulated radiation therapy boost for postoperative local recurrent rectal cancer: a planning study with comparison of DVH and NTCP. BMC Cancer, 2010, 10, 127.	1.1	23
510	Lysyl oxidase expression is an independent marker of prognosis and a predictor of lymph node metastasis in oral and oropharyngeal squamous cell carcinoma (OSCC). International Journal of Cancer, 2010, 126, 2653-2662.	2.3	56
511	Comparative study of tumor hypoxia by diffuse optical spectroscopy and immunohistochemistry in two tumor models. Journal of Biophotonics, 2010, 3, 743-751.	1.1	11
512	Pharmacokinetic Analysis of Hypoxia 18F-Fluoromisonidazole Dynamic PET in Head and Neck Cancer. Journal of Nuclear Medicine, 2010, 51, 37-45.	2.8	68
513	Exploring new potentials and generating hypothesis for management of locally advanced head neck cancer: Analysis of pooled data from two phase II trials. Journal of Cancer Research and Therapeutics, 2010, 6, 185.	0.3	2
514	Biological Rationales and Clinical Applications of Temperature Controlled Hyperthermia - Implications for Multimodal Cancer Treatments. Current Medicinal Chemistry, 2010, 17, 3045-3057.	1.2	80
515	Role of Anemia Prior to Radiation Treatment in Local Recurrence and Survival After Breast Conservation Treatment for Early-Stage Breast Cancer. Clinical Breast Cancer, 2010, 10, 74-80.	1.1	1
516	The remarkable yin and yang of tumour hypoxia. International Journal of Radiation Biology, 2010, 86, 907-917.	1.0	19
517	HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer. Radiotherapy and Oncology, 2010, 94, 30-35.	0.3	177
518	Implementation of hypoxia imaging into treatment planning and delivery. Radiotherapy and Oncology, 2010, 97, 172-175.	0.3	83
519	Assessing hypoxia in animal tumor models based on pharmocokinetic analysis of dynamic FAZA PET. Acta OncolA³gica, 2010, 49, 922-933.	0.8	35
520	Identifying hypoxia in human tumors: A correlation study between ¹⁸ F-FMISO PET and the Eppendorf oxygen-sensitive electrode. Acta Oncológica, 2010, 49, 934-940.	0.8	74
521	ldentifying pH independent hypoxia induced genes in human squamous cell carcinomas <i>in vitro</i> . Acta OncolA³gica, 2010, 49, 895-905.	0.8	88
523	Current state of knowledge regarding the use of antiangiogenic agents with radiation therapy. Cancer Treatment Reviews, 2011, 37, 476-86.	3.4	29
524	Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and 124I-cG250 PET/CT. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 411-420.	0.8	39

#	Article	IF	CITATIONS
525	Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck – A systematic review and meta-analysis. Radiotherapy and Oncology, 2011, 100, 22-32.	0.3	404
526	Changes in the fraction of total hypoxia and hypoxia subtypes in human squamous cell carcinomas upon fractionated irradiation: Evaluation using pattern recognition in microcirculatory supply units. Radiotherapy and Oncology, 2011, 101, 209-216.	0.3	17
527	miR-210 as a marker of chronic hypoxia, but not a therapeutic target in prostate cancer. Radiotherapy and Oncology, 2011, 101, 203-208.	0.3	37
528	Accessing radiation response using hypoxia PET imaging and oxygen sensitive electrodes: A preclinical study. Radiotherapy and Oncology, 2011, 99, 418-423.	0.3	40
529	Advancing radiation oncology through scientific publication – 100 volumes of Radiotherapy and Oncology. Radiotherapy and Oncology, 2011, 100, 1-6.	0.3	18
530	Antivascular therapy in gynaecological cancers. , 0, , 121-138.		1
531	Radiation therapy for neovascular age-related macular degeneration. Clinical Ophthalmology, 2011, 5, 57.	0.9	34
532	Nuclear factor-κB2/p100 promotes endometrial carcinoma cell survival under hypoxia in a HIF-1α independent manner. Laboratory Investigation, 2011, 91, 859-871.	1.7	33
533	Multi-modal strategies for overcoming tumor drug resistance: Hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology. Journal of Controlled Release, 2011, 155, 237-247.	4.8	112
534	Hypoxia-induced autophagic response is associated with aggressive phenotype and elevated incidence of metastasis in orthotopic immunocompetent murine models of head and neck squamous cell carcinomas (HNSCC). Experimental and Molecular Pathology, 2011, 90, 215-225.	0.9	38
535	Techniques of assessing hypoxia at the bench and bedside. Angiogenesis, 2011, 14, 119-124.	3.7	8
536	Necrosis and Angioinvasion Predict Adverse Outcome in Pancreatic Neuroendocrine Tumors After Curative Surgical Resection: Results of a Single enter Series. World Journal of Surgery, 2011, 35, 2764-2772.	0.8	14
537	18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma. Annals of Nuclear Medicine, 2011, 25, 625-633.	1.2	88
538	In vivo Identification and Specificity assessment of mRNA markers of hypoxia in human and mouse tumors. BMC Cancer, 2011, 11, 63.	1.1	12
539	Antivascular Effects of Neoadjuvant Androgen Deprivation for Prostate Cancer: An In Vivo Human Study Using Susceptibility and Relaxivity Dynamic MRI. International Journal of Radiation Oncology Biology Physics, 2011, 80, 721-727.	0.4	54
540	Synthesis, hypoxia-selective cytotoxicity of new 3-amino-1,2,4-benzotriazine-1,4-dioxide derivatives. European Journal of Medicinal Chemistry, 2011, 46, 919-926.	2.6	20
541	Inhibition of hypoxia-induced miR-155 radiosensitizes hypoxic lung cancer cells. Cancer Biology and Therapy, 2011, 12, 908-914.	1.5	108
542	Modelling of the oxygen enhancement ratio for ion beam radiation therapy. Physics in Medicine and Biology, 2011, 56, 3251-3268.	1.6	111

#	Article	IF	CITATIONS
545	Development of a Hypoxia Gene Expression Classifier with Predictive Impact for Hypoxic Modification of Radiotherapy in Head and Neck Cancer. Cancer Research, 2011, 71, 5923-5931.	0.4	226
546	Monte Carlo radiotherapy simulations of accelerated repopulation and reoxygenation for hypoxic head and neck cancer. British Journal of Radiology, 2011, 84, 903-918.	1.0	24
547	Dose prescription and treatment planning based on FMISO-PET hypoxia. Acta Oncológica, 2012, 51, 222-230.	0.8	85
548	Modeling the Spatial Distribution of Chronic Tumor Hypoxia: Implications for Experimental and Clinical Studies. Computational and Mathematical Methods in Medicine, 2012, 2012, 1-11.	0.7	50
549	Hypoxia in Head and Neck Squamous Cell Carcinoma. ISRN Otolaryngology, 2012, 2012, 1-8.	0.9	27
550	Revisiting the ultra-high dose rate effect: implications for charged particle radiotherapy using protons and light ions. British Journal of Radiology, 2012, 85, e933-e939.	1.0	62
551	An approach to identify, from DCE MRI, significant subvolumes of tumors related to outcomes in	1.6	59
552	Anthracycline Inhibits Recruitment of Hypoxia-inducible Transcription Factors and Suppresses Tumor Cell Migration and Cardiac Angiogenic Response in the Host. Journal of Biological Chemistry, 2012, 287, 34866-34882.	1.6	40
553	Suppression of HIF-1α expression and radiation resistance in acute hypoxic conditions. Experimental and Therapeutic Medicine, 2012, 3, 141-145.	0.8	13
554	18F-HX4 hypoxia imaging with PET/CT in head and neck cancer. Nuclear Medicine Communications, 2012, 33, 1096-1102.	0.5	83
555	Laser photocoagulation for choroidal neovascularization. , 2012, , 239-242.		0
556	Assessment of the novel tubulin-binding agent EHT 6706 in combination with ionizing radiation or chemotherapy. Investigational New Drugs, 2012, 30, 2173-2186.	1.2	2
557	Baseline Serum Lactate Dehydrogenase Levels for Patients Treated With Intensity-Modulated Radiotherapy for Nasopharyngeal Carcinoma: A Predictor of Poor Prognosis and Subsequent Liver Metastasis. International Journal of Radiation Oncology Biology Physics, 2012, 82, e359-e365.	0.4	100
558	Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck. Radiotherapy and Oncology, 2012, 102, 122-129.	0.3	196
559	Importance of hemoglobin concentration and its modification for the outcome of head and neck cancer patients treated with radiotherapy. Acta Oncológica, 2012, 51, 419-432.	0.8	71
560	Tumour microenvironment and radiation response in sarcomas originating from tumourigenic human mesenchymal stem cells. International Journal of Radiation Biology, 2012, 88, 457-465.	1.0	3
561	Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer. Clinical Cancer Research, 2012, 18, 758-770.	3.2	161
562	Syntheses of 2-Nitroimidazole Derivatives Conjugated with 1,4,7-Triazacyclononane- <i>N</i> , <i>N</i> ,′-Diacetic Acid Labeled with F-18 Using an Aluminum Complex Method for Hypoxia Imaging. Journal of Medicinal Chemistry, 2012, 55, 3155-3162.	2.9	42

#	Article	IF	CITATIONS
563	Hypoxia imaging using Positron Emission Tomography in non-small cell lung cancer: Implications for radiotherapy. Cancer Treatment Reviews, 2012, 38, 1027-1032.	3.4	37
564	On the structural modification of 2-nitroimidazole-99mTc(CO)3 complex, a hypoxia marker, for improving in vivo pharmacokinetics. Nuclear Medicine and Biology, 2012, 39, 1236-1242.	0.3	26
565	FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: Results from the DAHANCA 24 trial. Radiotherapy and Oncology, 2012, 105, 14-20.	0.3	266
566	Apparent diffusion coefficient correlation with oesophageal tumour stroma and angiogenesis. European Radiology, 2012, 22, 1172-1177.	2.3	64
567	Hypoxia Gene Expression Signatures as Prognostic and Predictive Markers in Head and Neck Radiotherapy. Seminars in Radiation Oncology, 2012, 22, 119-127.	1.0	66
568	Targeting tumor hypoxia in nasopharyngeal carcinoma. Head and Neck, 2013, 35, 133-145.	0.9	51
569	Hypoxia stimulates migration of breast cancer cells via the PERK/ATF4/LAMP3-arm of the unfolded protein response. Breast Cancer Research, 2013, 15, R2.	2.2	194
570	A 26-Gene Hypoxia Signature Predicts Benefit from Hypoxia-Modifying Therapy in Laryngeal Cancer but Not Bladder Cancer. Clinical Cancer Research, 2013, 19, 4879-4888.	3.2	214
571	Radiobiological description of the LET dependence of the cell survival of oxic and anoxic cells irradiated by carbon ions. Journal of Radiation Research, 2013, 54, 18-26.	0.8	51
572	Microenvironment and Radiation Therapy. BioMed Research International, 2013, 2013, 1-13.	0.9	122
573	Ultra-high field1H magnetic resonance imaging approaches for acute hypoxia. Acta Oncológica, 2013, 52, 1287-1292.	0.8	5
574	Exploring î"R ₂ * and î"R ₁ as imaging biomarkers of tumor oxygenation. Journal of Magnetic Resonance Imaging, 2013, 38, 429-434.	1.9	44
575	Trial Watch. Oncolmmunology, 2013, 2, e25595.	2.1	83
576	Molecular-targeted therapy hypoxia in head and neck squamous cell carcinoma patients. Molecular and Clinical Oncology, 2013, 1, 12-14.	0.4	1
577	Survival Benefit of Adding Chemotherapy to Intensity Modulated Radiation in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma. PLoS ONE, 2013, 8, e56208.	1.1	21
578	Analysis of Factors Contributing to the Low Survival of Cervical Cancer Patients Undergoing Radiotherapy in Kenya. PLoS ONE, 2013, 8, e78411.	1.1	75
579	P-glycoprotein Inhibition as a Therapeutic Approach for Overcoming Multidrug Resistance in Cancer: Current Status and Future Perspectives. Current Cancer Drug Targets, 2013, 13, 326-346.	0.8	320
580	Epimacular brachytherapy for wet AMD: current perspectives. Clinical Ophthalmology, 2014, 8, 1661.	0.9	7

#	Article	IF	CITATIONS
581	The Molecular Crosstalk between the MET Receptor Tyrosine Kinase and the DNA Damage Response—Biological and Clinical Aspects. Cancers, 2014, 6, 1-27.	1.7	32
582	Magnetic therapeutic delivery using navigable agents. Therapeutic Delivery, 2014, 5, 189-204.	1.2	20
583	Selective expression of transgene using hypoxia-inducible trans-splicing group I intron ribozyme. Journal of Biotechnology, 2014, 192, 22-27.	1.9	3
584	The Clinical Importance of Assessing Tumor Hypoxia: Relationship of Tumor Hypoxia to Prognosis and Therapeutic Opportunities. Antioxidants and Redox Signaling, 2014, 21, 1516-1554.	2.5	323
585	Quantitative Profiling of Chromatome Dynamics Reveals a Novel Role for HP1BP3 in Hypoxia-induced Oncogenesis. Molecular and Cellular Proteomics, 2014, 13, 3236-3249.	2.5	38
586	Tumor Radiation Biology. , 2014, , 97-119.		2
587	Molecular Determinants of Head and Neck Cancer. , 2014, , .		2
588	Clinical Imaging of Hypoxia. Cancer Drug Discovery and Development, 2014, , 179-201.	0.2	0
589	Head and Neck Tumor Hypoxia Imaging by 18F-Fluoroazomycin-arabinoside (18F-FAZA)-PET. Clinical Nuclear Medicine, 2014, 39, 44-48.	0.7	48
590	Taxanes as radiosensitizers. Anti-Cancer Drugs, 2014, 25, 502-511.	0.7	25
591	Role of Vascular Endothelial Growth Factor in Clinically Localized Prostate Cancer Treated with Radiation Therapy. Balkan Medical Journal, 2014, 33, 43-49.	0.3	3
592	Regulation of O2 consumption by the PI3K and mTOR pathways contributes to tumor hypoxia. Radiotherapy and Oncology, 2014, 111, 72-80.	0.3	37
593	A prospective clinical study of 18 F-FAZA PET-CT hypoxia imaging in head and neck squamous cell carcinoma before and during radiation therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1544-1552.	3.3	97
594	A retrospective study of urokinase-type plasminogen activator receptor (uPAR) as a prognostic factor in cancer of the uterine cervix. International Journal of Clinical Oncology, 2014, 19, 1059-1064.	1.0	5
595	Hypoxia and Cancer. Cancer Drug Discovery and Development, 2014, , .	0.2	7
596	Cytoglobin in tumor hypoxia: novel insights into cancer suppression. Tumor Biology, 2014, 35, 6207-6219.	0.8	18
597	A study on nitroimidazole-99mTc(CO)3 complexes as hypoxia marker: Some observations towards possible improvement in in vivo efficacy. Nuclear Medicine and Biology, 2014, 41, 600-610.	0.3	26
598	Does Erythropoietin Have a Role in the Treatment of Î ² -Hemoglobinopathies?. Hematology/Oncology Clinics of North America, 2014, 28, 249-263.	0.9	10

#	Article	IF	CITATIONS
599	Serine Catabolism Regulates Mitochondrial Redox Control during Hypoxia. Cancer Discovery, 2014, 4, 1406-1417.	7.7	342
600	Targeting RPL39 and MLF2 reduces tumor initiation and metastasis in breast cancer by inhibiting nitric oxide synthase signaling. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 8838-8843.	3.3	99
601	Tumor Hypoxia. , 2014, , 205-222.		0
602	Prognostic value of tumour blood flow, [18F]EF5 and [18F]FDG PET/CT imaging in patients with head and neck cancer treated with radiochemotherapy. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 2042-2050.	3.3	44
603	Bringing the heavy: carbon ion therapy in the radiobiological and clinical context. Radiation Oncology, 2014, 9, 88.	1.2	114
604	The Tumor Radiobiology of SRS and SBRT: Are More Than the 5 Rs Involved?. International Journal of Radiation Oncology Biology Physics, 2014, 88, 254-262.	0.4	462
605	18F-Fluorodeoxyglucose Uptake and Tumor Hypoxia: Revisit 18F-Fluorodeoxyglucose in Oncology Application. Translational Oncology, 2014, 7, 240-247.	1.7	35
606	Spatiotemporal Stability of Cu-ATSM and FLT Positron Emission Tomography Distributions During Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2014, 89, 399-405.	0.4	21
607	Molecular Imaging of Tumor Hypoxia with Positron Emission Tomography. Radiation Research, 2014, 181, 335-349.	0.7	41
608	Hypoxic regulation of the PERK/ATF4/LAMP3â€arm of the unfolded protein response in head and neck squamous cell carcinoma. Head and Neck, 2015, 37, 896-905.	0.9	28
609	18F-fluoromisonidazole PET reveals spatial and temporal heterogeneity of hypoxia in mouse models of human non-small-cell lung cancer. Future Oncology, 2015, 11, 2841-2849.	1.1	5
610	Towards Multidimensional Radiotherapy: Key Challenges for Treatment Individualisation. Computational and Mathematical Methods in Medicine, 2015, 2015, 1-8.	0.7	15
611	Therapeutic Implications for Overcoming Radiation Resistance in Cancer Therapy. International Journal of Molecular Sciences, 2015, 16, 26880-26913.	1.8	165
612	Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer. Cancer Biology and Therapy, 2015, 16, 438-449.	1.5	46
613	Ill-posed problem and regularization in reconstruction of radiobiological parameters from serial tumor imaging data. Physics in Medicine and Biology, 2015, 60, 8491-8503.	1.6	10
614	Biology of Hypoxia. Seminars in Nuclear Medicine, 2015, 45, 101-109.	2.5	121
615	Molecular imaging of hypoxia in non-small-cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 956-976.	3.3	50
616	The usability of a 15-gene hypoxia classifier as a universal hypoxia profile in various cancer cell types. Radiotherapy and Oncology, 2015, 116, 346-351.	0.3	26

#	Article	IF	CITATIONS
617	Molecular Imaging Biomarkers of Resistance to Radiation Therapy for Spontaneous Nasal Tumors in Canines. International Journal of Radiation Oncology Biology Physics, 2015, 91, 787-795.	0.4	19
618	Functional imaging for radiotherapy treatment planning: current status and future directions—a review. British Journal of Radiology, 2015, 88, 20150056.	1.0	64
619	Gene Expression Signatures as Biomarkers of Tumour Hypoxia. Clinical Oncology, 2015, 27, 547-560.	0.6	95
620	Hyperpolarized magnetic resonance spectroscopy for assessing tumor hypoxia. Acta Oncológica, 2015, 54, 1393-1398.	0.8	8
621	Hypoxia-targeted 1311 therapy of hepatocellular cancer after systemic mesenchymal stem cell-mediated sodium iodide symporter gene delivery. Oncotarget, 2016, 7, 54795-54810.	0.8	31
622	Pathophysiological Basis for the Formation of the Tumor Microenvironment. Frontiers in Oncology, 2016, 6, 66.	1.3	152
623	Translational Research to Improve the Efficacy of Carbon Ion Radiotherapy: Experience of Gunma University. Frontiers in Oncology, 2016, 6, 139.	1.3	20
624	Switching between Magnetotactic and Aerotactic Displacement Controls to Enhance the Efficacy of MC-1 Magneto-Aerotactic Bacteria as Cancer-Fighting Nanorobots. Micromachines, 2016, 7, 97.	1.4	15
625	In Vivo Interrogation of the Hypoxic Transcriptome of Solid Tumors: Optimizing Hypoxic Probe Labeling with Laser Capture Microdissection for Isolation of High-Quality RNA for Deep Sequencing Analysis. Advances in Experimental Medicine and Biology, 2016, 899, 41-58.	0.8	1
626	HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Radiotherapy and Oncology, 2016, 121, 364-373.	0.3	130
627	Metabolic response of lung cancer cells to radiation in a paper-based 3D cell culture system. Biomaterials, 2016, 95, 47-59.	5.7	57
628	Assessment of predictive molecular variables in feline oral squamous cell carcinoma treated with stereotactic radiation therapy. Veterinary and Comparative Oncology, 2016, 14, 39-57.	0.8	24
629	Reproducibility of 18F-fluoromisonidazole intratumour distribution in non-small cell lung cancer. EJNMMI Research, 2016, 6, 79.	1.1	25
630	Adaptation of the microdosimetric kinetic model to hypoxia. Physics in Medicine and Biology, 2016, 61, 7586-7599.	1.6	28
631	A theoretical stochastic control framework for adapting radiotherapy to hypoxia. Physics in Medicine and Biology, 2016, 61, 7136-7161.	1.6	14
632	Oxygen-Related Differences in Cellular and Vesicular Phenotypes Observed for Ovarian Cell Cancer Lines. Journal of Circulating Biomarkers, 2016, 5, 1.	0.8	13
633	Molecular Radio-Oncology. Recent Results in Cancer Research, 2016, , .	1.8	1
634	Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2016, , .	0.8	3

#	Article	IF	CITATIONS
635	Hypoxia as a Biomarker and for Personalized Radiation Oncology. Recent Results in Cancer Research, 2016, 198, 123-142.	1.8	26
636	Targeting hypoxia to overcome radiation resistance in head & neck cancers: real challenge or clinical fairytale?. Expert Review of Anticancer Therapy, 2016, 16, 751-758.	1.1	36
637	Noninvasive PET Imaging and Tracking of Engineered Human Muscle Precursor Cells for Skeletal Muscle Tissue Engineering. Journal of Nuclear Medicine, 2016, 57, 1467-1473.	2.8	12
638	Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study. Chinese Journal of Cancer, 2016, 35, 2.	4.9	62
639	Impact of pretreatment whole-tumor perfusion computed tomography and 18F-fluorodeoxyglucose positron emission tomography/computed tomography measurements on local control of non–small cell lung cancer treated with stereotactic body radiotherapy. Journal of Radiation Research, 2016, 57, 533-540.	0.8	15
640	The Effects of Severe Hypoxia on Glycolytic Flux and Enzyme Activity in a Model of Solid Tumors. Journal of Cellular Biochemistry, 2016, 117, 1890-1901.	1.2	23
641	Neutral 99mTc(CO)3 complexes of "clicked―nitroimidazoles for the detection of tumor hypoxia. Journal of Radioanalytical and Nuclear Chemistry, 2016, 307, 69-77.	0.7	8
642	Tissue Discs: A 3D Model for Assessing Modulation of Tissue Oxygenation. Advances in Experimental Medicine and Biology, 2016, 876, 169-175.	0.8	1
643	Oxygen Transport to Tissue XXXVII. Advances in Experimental Medicine and Biology, 2016, , .	0.8	8
644	Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(â^') HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG. Clinical Cancer Research, 2016, 22, 2639-2649.	3.2	127
645	Radiation oncology in the era of precision medicine. Nature Reviews Cancer, 2016, 16, 234-249.	12.8	636
646	Prognostic value of PET/CT with 18F-fluoroazomycin arabinoside for patients with head and neck squamous cell carcinomas receiving chemoradiotherapy. Annals of Nuclear Medicine, 2016, 30, 217-224.	1.2	15
647	The role of new PET tracers for lung cancer. Lung Cancer, 2016, 94, 7-14.	0.9	47
648	Comparison of treatment planning parameters for dose painting head and neck plans delivered with tomotherapy. British Journal of Radiology, 2016, 89, 20150970.	1.0	16
649	Feasibility of 18F-Fluoromisonidazole Kinetic Modeling in Head and Neck Cancer Using Shortened Acquisition Times. Journal of Nuclear Medicine, 2016, 57, 334-341.	2.8	16
650	PET-based quantification of statistical properties of hypoxic tumor subvolumes in head and neck cancer. Physica Medica, 2016, 32, 23-35.	0.4	20
651	Dose-Response Modifiers in Radiation Therapy. , 2016, , 51-62.e3.		3
652	Oxygen imaging of living cells and tissues using luminescent molecular probes. Journal of Photochemistry and Photobiology C: Photochemistry Reviews, 2017, 30, 71-95.	5.6	98

#	Article	IF	CITATIONS
653	Prognostic value of dynamic hypoxia PET in head and neck cancer: Results from a planned interim analysis of a randomized phase II hypoxia-image guided dose escalation trial. Radiotherapy and Oncology, 2017, 124, 526-532.	0.3	107
654	Vascularity and Tumor Size are Significant Predictors for Recurrence after Resection of a Pancreatic Neuroendocrine Tumor. Annals of Surgical Oncology, 2017, 24, 2363-2370.	0.7	25
655	Realizing the Potential of Vascular Targeted Therapy: The Rationale for Combining Vascular Disrupting Agents and Anti-Angiogenic Agents to Treat Cancer. Cancer Investigation, 2017, 35, 519-534.	0.6	54
656	Hypoxia PET imaging techniques: data acquisition and analysis. Clinical and Translational Imaging, 2017, 5, 489-496.	1.1	3
657	Simulation of head and neck cancer oxygenation and doubling time in a 4D cellular model with angiogenesis. Scientific Reports, 2017, 7, 11037.	1.6	9
658	Oxygen generating nanoparticles for improved photodynamic therapy of hypoxic tumours. Journal of Controlled Release, 2017, 264, 333-340.	4.8	79
659	Molecular targeting of hypoxia in radiotherapy. Advanced Drug Delivery Reviews, 2017, 109, 45-62.	6.6	146
660	Anaemia in Cancer Patients Undergoing Radiotherapy and Chemotherapy at the National Hospital, Abuja. Journal of Neoplasm, 2017, 02, .	0.1	0
661	Survival and Toxicities of IMRT Based on the RTOG Protocols in Patients with Nasopharyngeal Carcinoma from the Endemic Regions of China. Journal of Cancer, 2017, 8, 3718-3724.	1.2	25
662	[18F]Fluoromisonidazole PET in rectal cancer. EJNMMI Research, 2017, 7, 78.	1.1	18
663	Revisit 18F-fluorodeoxyglucose oncology positron emission tomography: "systems molecular imaging―of glucose metabolism. Oncotarget, 2017, 8, 43536-43542.	0.8	34
664	DAHANCA 10 – Effect of darbepoetin alfa and radiotherapy in the treatment of squamous cell carcinoma of the head and neck. A multicenter, open-label, randomized, phase 3 trial by the Danish head and neck cancer group. Radiotherapy and Oncology, 2018, 127, 12-19.	0.3	32
665	Development and Validation of a Gene Signature for Patients with Head and Neck Carcinomas Treated by Postoperative Radio(chemo)therapy. Clinical Cancer Research, 2018, 24, 1364-1374.	3.2	45
666	Novel microtubule inhibitor MPT0B098 inhibits hypoxia-induced epithelial-to-mesenchymal transition in head and neck squamous cell carcinoma. Journal of Biomedical Science, 2018, 25, 28.	2.6	10
667	Selecting patients for hyperthermia combined with preoperative chemoradiotherapy for locally advanced rectal cancer. International Journal of Clinical Oncology, 2018, 23, 287-297.	1.0	5
668	Transcutaneous carbon dioxide enhances the antitumor effect of radiotherapy on oral squamous cell carcinoma. Oncology Reports, 2018, 40, 434-442.	1.2	4
669	Computational models and tools. Medical Physics, 2018, 45, e1073-e1085.	1.6	5
670	Arene Ruthenium Metalla-Assemblies with Anthracene Moieties for PDT Applications. Inorganics, 2018, 6, 97.	1.2	14

#	ARTICLE Three-dimensional alginate hydrogels for radiobiological and metabolic studies of cancer cells.	IF 2.5	CITATIONS
672	Colloids and Surfaces B: Biointerfaces, 2018, 171, 197-204. Correlation of hypoxia status with radiosensitizing effects of sodium glycididazole: A preclinical study. Oncology Letters, 2018, 15, 6481-6488.	0.8	4
673	The Future of Radiotherapy in Bladder Cancer. , 2018, , 123-129.		0
675	Preparation and preliminary evaluation of a tris-metronidazole-99mTc(CO)3 complex for targeting tumor hypoxia. Journal of Radioanalytical and Nuclear Chemistry, 2018, 317, 1203-1210.	0.7	6
676	Assessment of soft-tissue sarcomas perfusion using data-driven techniques. , 2018, , .		0
677	High Single Doses of Radiation May Induce Elevated Levels of Hypoxia in Early-Stage Non-Small Cell Lung Cancer Tumors. International Journal of Radiation Oncology Biology Physics, 2018, 102, 174-183.	0.4	36
678	Approaches to combat hypoxia in cancer therapy and the potential for in silico models in their evaluation. Physica Medica, 2019, 64, 145-156.	0.4	15
679	The Potential Role of Radiomics and Radiogenomics in Patient Stratification by Tumor Hypoxia Status. Journal of the American College of Radiology, 2019, 16, 1329-1337.	0.9	16
680	Acute Hypoxia Profile is a Stronger Prognostic Factor than Chronic Hypoxia in Advanced Stage Head and Neck Cancer Patients. Cancers, 2019, 11, 583.	1.7	28
681	Predictive Value of Pretherapeutic Maximum Standardized Uptake Value (Suvmax) In Laryngeal and Hypopharyngeal Cancer. Scientific Reports, 2019, 9, 8972.	1.6	21
682	Hypoxia and angiogenic biomarkers in prostate cancer after external beam radiotherapy (EBRT) alone or combined with high-dose-rate brachytherapy boost (HDR-BTb). Radiotherapy and Oncology, 2019, 137, 38-44.	0.3	6
683	Prospective Evaluation of a Tumor Control Probability Model Based on Dynamic ¹⁸ F-FMISO PET for Head and Neck Cancer Radiotherapy. Journal of Nuclear Medicine, 2019, 60, 1698-1704.	2.8	37
684	Correlation between FMISO-PET based hypoxia in the primary tumour and in lymph node metastases in locally advanced HNSCC patients. Clinical and Translational Radiation Oncology, 2019, 15, 108-112.	0.9	9
685	Oxygen-Guided Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2019, 103, 977-984.	0.4	59
686	FMISO-PET-based lymph node hypoxia adds to the prognostic value of tumor only hypoxia in HNSCC patients. Radiotherapy and Oncology, 2019, 130, 97-103.	0.3	14
687	Upconversion-based photodynamic cancer therapy. Coordination Chemistry Reviews, 2019, 379, 82-98.	9.5	249
688	Fabrication of hypoxia-responsive and uperconversion nanoparticles-modified RBC micro-vehicles for oxygen delivery and chemotherapy enhancement. Biomaterials Science, 2020, 8, 4595-4602.	2.6	17
689	Patient-Derived Xenograft and Organoid Models for Precision Medicine Targeting of the Tumour Microenvironment in Head and Neck Cancer. Cancers, 2020, 12, 3743.	1.7	19

#	Article	IF	CITATIONS
690	Targeting the Tumor Core: Hypoxia-Responsive Nanoparticles for the Delivery of Chemotherapy to Pancreatic Tumors. Molecular Pharmaceutics, 2020, 17, 2849-2863.	2.3	40
691	Imaging of Tumor Hypoxia for Radiotherapy: Current Status and Future Directions. Seminars in Nuclear Medicine, 2020, 50, 562-583.	2.5	40
692	Four decades with ESTRO. Radiotherapy and Oncology, 2020, 142, 1-5.	0.3	5
693	Most Cited Articles in Head and Neck Oncology. Ear, Nose and Throat Journal, 2020, 100, 014556132093492.	0.4	2
694	Glycoprotein Nonmetastatic Melanoma Protein B as Potential Imaging Marker in Posttherapeutic Metastatic Head and Neck Cancer. Otolaryngology - Head and Neck Surgery, 2020, 163, 1202-1208.	1.1	2
695	<i>In vitro</i> simultaneous mapping of the partial pressure of oxygen, pH and inorganic phosphate using electron paramagnetic resonance. Analyst, The, 2020, 145, 3236-3244.	1.7	9
696	Predictive quantitative ultrasound radiomic markers associated with treatment response in head and neck cancer. Future Science OA, 2020, 6, FSO433.	0.9	18
697	Evaluation of CT-based radiomics signature and nomogram as prognostic markers in patients with laryngeal squamous cell carcinoma. Cancer Imaging, 2020, 20, 28.	1.2	31
698	The clinical utility of imaging methods used to measure hypoxia in cervical cancer. British Journal of Radiology, 2020, 93, 20190640.	1.0	9
699	Prediction of radiation-induced mucositis of H&N cancer patients based on a large patient cohort. Radiotherapy and Oncology, 2020, 147, 15-21.	0.3	15
701	The Role of Hypoxia in Radiation Response. , 2016, , 29-42.		1
703	Flavin Mononucleotide-Based Fluorescent Proteins Function in Mammalian Cells without Oxygen Requirement. PLoS ONE, 2012, 7, e43921.	1.1	35
704	Reducing Tumour Hypoxia via Oral Administration of Oxygen Nanobubbles. PLoS ONE, 2016, 11, e0168088.	1.1	52
705	An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment, 2016, 20, 1-188.	1.3	51
706	Relationship between anemia and tumor hypoxia. , 2002, , 117-125.		2
707	Hypoxia in Head and Neck Cancer. , 2017, , 59-95.		0
708	Transiently hypoxic tumour cell turnover and radiation sensitivity in human tumour xenografts. British Journal of Cancer, 2022, 126, 1616-1626.	2.9	5